Cell Metab by Nakamura, Michinari et al.
Glycogen Synthase Kinase-3α Promotes Fatty Acid Uptake and 
Lipotoxic Cardiomyopathy
Michinari Nakamura1, Tong Liu2, Seema Husain3, Peiyong Zhai1, Junco S. Warren4, Chiao-
Po Hsu5, Takahisa Matsuda1, Christopher J. Phiel6, James E. Cox7, Bin Tian3, Hong Li2, 
Junichi Sadoshima1,8,*
1.
 Department of Cell Biology and Molecular Medicine, Cardiovascular Research Institute, Rutgers 
New Jersey Medical School, Newark, New Jersey
2.
 Center for Advanced Proteomics Core, Department of Biochemistry & Molecular Biology, 
Rutgers New Jersey Medical School, Newark, New Jersey
3.
 Department of Microbiology, Biochemistry, and Molecular Genetics, Rutgers New Jersey 
Medical School, Newark, New Jersey
4.
 Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt 
Lake City, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, 
Utah
5.
 Division of Cardiovascular Surgery, Department of Surgery, Taipei Veterans General Hospital, 
National Yang-Ming University School of Medicine, Taiwan
6.
 Department of Integrative Biology, University of Colorado Denver, Denver, Colorado
7.
 Metabolomics Core Research Facility, University of Utah, Salt Lake City, Utah, Department of 
Biochemistry, University of Utah, Salt Lake City, Utah
8.
 Lead Contact
Summary
Obesity induces lipotoxic cardiomyopathy, a condition in which lipid accumulation in 
cardiomyocytes causes cardiac dysfunction. Here, we show that glycogen synthase kinase-3α 
(GSK-3α) mediates lipid accumulation in the heart. Fatty acids (FAs) upregulate GSK-3α, which 
phosphorylates PPARα at Ser280 in the ligand binding domain (LBD). This modification ligand-
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independently enhances transcription of a subset of PPARα targets, selectively stimulating FAs 
uptake and storage, but not oxidation, thereby promoting lipid accumulation. Constitutively-active 
GSK-3α, but not GSK-3β, was sufficient to drive PPARα signaling, while cardiac-specific 
knockdown of GSK-3α, but not GSK-3β, or replacement of PPARα Ser280 with Ala conferred 
resistance to lipotoxicity in the heart. Fibrates, PPARα ligands, inhibited phosphorylation of 
PPARα at Ser280 by inhibiting the interaction of GSK-3α with the LBD of PPARα, thereby 
reversing lipotoxic cardiomyopathy. These results suggest that GSK-3α promotes lipid anabolism 
through PPARα-Ser280 phosphorylation, which underlies the development of lipotoxic 
cardiomyopathy in the context of obesity.
eTOC blurb
Nakamura et al. investigate the mechanisms underlying the development of lipotoxic 
cardiomyopathy. Fatty acids-induced upregulation of GSK-3α acts as a central regulator of cardiac 
fatty acid metabolism by stimulating a biased PPARα transcriptional response via Ser280-
phosphorylation, favoring fatty acid uptake. A reversal of Ser280-phosphorylation attenuates 
lipotoxicity.
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Introduction
Fatty acids are major substrates for ATP generation in oxidative tissues, including the adult 
heart (Lopaschuk et al., 2010). Derangement in fatty acid metabolism has significant 
consequences for cellular functions, leading to organ failure. Decreases in the level of fatty 
acid oxidation (FAO) are a common feature of heart failure (Neubauer, 2007), a condition in 
which cardiac output is decreased due to dysfunction or death of individual cardiomyocytes 
(CMs). In lipotoxicity, an imbalance between uptake or synthesis of fatty acid and its 
consumption results in intracellular accumulation of lipid intermediates, which induces 
cellular dysfunction and death in non-adipose tissues, including the kidney, liver, skeletal 
muscle, and heart (Goldberg et al., 2012). Lipotoxic cardiomyopathy is the major 
mechanism through which patients with insulin resistance, diabetes and obesity develop 
cardiac hypertrophy and dysfunction (Schilling and Mann, 2012), and is an important cause 
of heart failure with preserved ejection fraction (HFpEF). However, how the balance of fatty 
acid metabolism is disrupted in obesity remains poorly understood.
Peroxisome proliferator-activated receptor α (PPARα) is a nuclear receptor transcription 
factor that plays a key role in regulating fatty acid metabolism in the heart (Vega and Kelly, 
2017). Genetic overexpression of PPARα in the heart mimics the phenotype of lipotoxic 
cardiomyopathy (Finck et al., 2002) whereas knockdown of PPARα attenuates lipotoxic 
cardiomyopathy (Finck et al., 2003), suggesting that PPARα plays an important role in the 
pathogenesis of lipotoxic cardiomyopathy. However, how endogenous PPARα is 
functionally modulated in the presence of obesity and diabetes and how its modification 
contributes to lipotoxicity remain poorly understood. In particular, given that PPARα 
broadly controls expression of genes involved in fatty acid metabolism, including uptake, 
storage and oxidation, it remains unclear how changes in the level or the activity of PPARα 
alone can cause the imbalance between the various fatty acid metabolic mechanisms in turn 
leads to accumulation of lipid intermediates in CMs.
Through our extensive search for the molecular mechanism mediating lipotoxic 
cardiomyopathy in mouse models of obesity and diabetes induced by high-fat diet (HFD) 
consumption and genetic alteration, we found that activation of GSK-3α, an isoform of 
GSK-3, is essential for the induction of lipotoxic cardiomyopathy. Thus, the goal in this 
study was to elucidate the molecular mechanism by which GSK-3α controls lipid 
accumulation in CMs in the presence of metabolic syndrome. Our results show that fatty 
acids upregulate nuclear GSK-3α, which phosphorylates PPARα at Ser280 in the ligand 
binding domain (LBD). This modification induces transcription of genes involved in fatty 
acid uptake and storage, but not oxidation. Our data suggest that GSK-3α acts as a fatty 
acids sensor in CMs, stimulating lipid uptake and promoting its accumulation in CMs 
through biased activation of PPARα, and that this process underlies the development of 
lipotoxic cardiomyopathy in obesity and diabetes.
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Results
Cardiac-specific haploinsufficiency of GSK-3α ameliorates HFD-induced cardiomyopathy
In order to elucidate changes in the signaling mechanism during the development of 
lipotoxic cardiomyopathy, we analyzed publicly available gene expression datasets from the 
hearts of obese (GSE16790) and diabetic mice (GSE36875). In order to distinguish the 
mechanism of cardiomyopathy caused by obesity or type II diabetes, on which we are 
focusing, from that caused by type I diabetes, we excluded gene sets upregulated in 
streptozotocin-induced diabetic hearts (GSE5606). Twenty-six genes were upregulated in the 
hearts of both obese and diabetic mice (Figure 1A). Consistent with the nature of obesity-
related cardiomyopathy, analysis of gene ontology terms showed that the metabolic process 
(GO: 0008152), containing 13 genes, represented the largest biological process among the 
26 overlapping genes, wherein GSK-3α was the only kinase (Figure 1B). We validated the 
upregulation of GSK-3α in a diet-induced obese model. Obesity induced by HFD (60% kcal 
from fat) consumption elicited lipotoxic cardiomyopathy with accumulation of 
intramyocardial lipid in the heart. In line with the paper by Bugger and Abel, we also 
identified insulin resistance in the heart, as evidenced by decreased Akt phosphorylation in 
response to insulin (Bugger and Abel, 2009) (Figure S1A). Since Akt, which negatively 
regulates GSK-3α, is downregulated and GSK-3α is translocated to the nucleus in response 
to stress (Azoulay-Alfaguter et al., 2011) (Figure S4A), we evaluated the activity of GSK-3α 
in the nucleus in response to HFD, using immune-complex in vitro kinase assays with 
recombinant β-catenin as a substrate. GSK-3α was activated by HFD consumption (Figures 
1C, 1D). GSK-3α was similarly activated in genetically obese mouse (ob/ob) hearts (Figure 
S1B). These results suggest that the activity of GSK-3α is significantly increased in the 
hearts of mice fed a HFD and genetically obese mice.
In order to examine the functional significance of GSK-3α activation in the heart in response 
to HFD consumption, we fed cardiac-specific GSK-3α heterozygous knockout (GSK-3α 
cHKO) and heterozygous floxed (control) mice with HFD for up to 14 weeks (Figure S1C). 
Although there was no difference in body weight gain, food intake or systemic insulin 
resistance between control and GSK-3α cHKO mice (Figures S1D–F), there was a clear 
attenuation in HFD-induced cardiac and individual CM hypertrophy in GSK-3α cHKO mice 
(Figures 1E, 1F, S1G). Left ventricular (LV) systolic function was preserved in both groups 
(Figure S1H) after HFD consumption. However, HFD induced diastolic dysfunction in 
control mice, as evidenced by a longer deceleration time (DT) of the transmitral flow 
observed via Doppler echocardiography, a left upward shift of the slope of the end-diastolic 
pressure-volume (PV) relation loop (EDPVR), and an increase in Tau in PV loop analyses 
(Pacher et al., 2008) (Figures 1G, 1H, S1I–K). The HFD-induced diastolic dysfunction was 
significantly alleviated in GSK-3α cHKO mice. HFD consumption did not affect maximum 
LV pressure or stroke work in either control or GSK-3a cHKO mice (Figures S1L, S1M). 
These results indicate that HFD-mediated cardiac hypertrophy (lipotoxic cardiomyopathy) 
may not be induced by altered blood pressure within 3 months, and that suppression of 
hypertrophy does not lead to markedly elevated wall stress; thus, the overall function of the 
heart in GSK-3α cHKO mice is improved. Together, these results suggest that aberrant 
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activation of GSK-3α plays a critical role in the development of cardiomyopathy in response 
to HFD consumption.
Intramyocardial lipid accumulation, as assessed by Oil Red O staining, and palmitic acid 
oxidation, assessed using 3H-palmitic acid, were increased in control mouse hearts in 
response to HFD, but were markedly attenuated in GSK-3α cHKO mice (Figures 1I, 1J). A 
Seahorse analysis indicated that the mitochondrial FAO rate was also increased in CMs 
isolated from the hearts of control mice fed HFD but was significantly suppressed in CMs 
isolated from the hearts of GSK-3α cHKO mice fed HFD (Figures S2A–D). In addition, 
picric acid Sirius red staining showed reduced cardiac fibrosis in GSK-3α cHKO mice 
compared to in control mice (Figure 1K). Glycogen storage in the heart was not significantly 
altered by GSK-3α suppression (Figures S2E, S2F). Notably, GSK-3β cHKO mice 
developed cardiac systolic dysfunction and more prominent myocardial lipid accumulation 
than control mice in response to HFD (Figures S2G–K), suggesting that the role of GSK-3 is 
isoform-dependent. HFD upregulated mRNA expression of genes involved in fatty acid 
metabolism in control mice, whereas these changes were attenuated in GSK-3α cHKO mice 
(Figure 1L). In contrast, gene expression of inflammatory cytokines and other transcription 
factors related to cardiac metabolism did not differ significantly between control and 
GSK-3α cHKO mice fed a HFD. These results indicate that alleviation of diet-induced 
cardiomyopathy and metabolic remodeling in GSK-3α cHKO mice may be mediated, at 
least in part, at the level of transcription of genes involved in fatty acid metabolism.
Since HFD activates GSK-3α, we hypothesized that activation of GSK-3α is sufficient to 
deregulate expression of fatty acid metabolism-related genes. We analyzed microarray data 
obtained from the hearts of GSK-3α S21A homozygous knockin (KI) mice harboring 
constitutively active GSK-3α and wild-type (WT) mice fed normal chow (NC) (Matsuda et 
al., 2008). Although there was no overt cardiac phenotype at the age of 3 months, the gene 
set enrichment analysis (GSEA) showed that, in the hearts of GSK-3α S21A KI mice, PPAR 
signaling is the most significantly enriched among the upregulated gene sets related to 
energy metabolism (Figure 1M, Table 1 and Table S1). In contrast, GSK-3β S9A 
homozygous KI mice, harboring constitutively active GSK-3β, displayed downregulation of 
genes involved in cardiac fatty acid metabolism (Figure S2L). One PPAR target gene, CD36, 
was significantly increased in GSK-3α S21A KI mice (Figure S2M). Consistent with the 
increased CD36 mRNA expression, both palmitate uptake into the heart and intramyocardial 
lipid accumulation were increased in GSK-3α S21A KI mice (Figures S2N, S2O). These 
results are also consistent with the absence of an increase in expression of CD36 in response 
to HFD consumption in GSK-3α cHKO mice (Figure 1L), which could partially explain the 
lower FAO, potentially resulting from less fatty acid import, in GSK-3α cHKO mice. Taken 
together, these results indicate that upregulation of GSK-3α, but not GSK-3β, positively 
regulates lipid metabolism through PPAR modification in the heart.
GSK-3α phosphorylates PPARα at Ser280, located in the ligand binding domain
Since the PPARα transcription factor plays a major role in the regulation of fatty acid 
metabolism in the heart, we examined the physical interaction between GSK-3α and 
PPARα. YFP-tagged PPARα pulled down endogenous GSK-3α, but not GSK-3β, in CMs 
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(Figures 2A, S3A). Anti-FLAG immunoprecipitation assays showed that GSK-3α and 
PPARα interact with one another in mouse hearts overexpressing FLAG-tagged PPARα 
(Figure 2B). Co-immunoprecipitation assays also revealed that endogenous GSK-3α and 
endogenous PPARα interact with one another in CMs in vitro (Figure 2C). In addition, in 
vitro binding assays using recombinant GST-PPARα and recombinant GSK-3α or GSK-3β 
showed that GSK-3α, but not GSK-3β, directly interacts with PPARα (Figures 2D, S3B). 
We further evaluated which amino acids of PPARα are involved in the interaction with 
endogenous GSK-3α, using truncated recombinant GST-PPARα and CM lysates (Figures 
2E, 2F). Although full-length (FL) and N-terminally truncated (T5) GST-PPARα were able 
to pull down endogenous GSK-3α, C-terminally truncated GST-PPARα (T1-T4) and GST 
alone failed to pull down GSK-3α, suggesting that the LBD of PPARα interacts with 
GSK-3α (Figure 2G).
We then hypothesized that GSK-3α phosphorylates PPARα. In vitro kinase assays showed 
that both GST-PPARα-FL and a PPARα fragment (amino acids 170–430) containing the 
LBD are phosphorylated by GSK-3α (Figure S3C). Furthermore, mass spectrometry 
analysis showed that Ser280 of PPARα, located in the LBD and highly conserved in PPARα 
across species, is phosphorylated by GSK-3α (Figures 2H, S3D). We therefore generated an 
antibody against PPARα phosphorylated at Ser280. This antibody effectively detected GST-
tagged WT PPARα, but not GST-tagged PPARα-S280A, a non-phosphorylatable mutant, 
after in vitro kinase assays with GSK-3α (Figures S3E, S3F). Using this antibody, we 
confirmed that YFP-tagged PPARα-WT, but not PPARα-S280A, was phosphorylated in the 
presence of GSK-3α overexpression but not GSK-3α knockdown in CMs (Figure S3G). 
YFP-tagged PPARα-S280D, a phospho-mimetic mutant, was detected by the phospho-
specific antibody even in cells in which GSK-3α was knocked down. Immunoblot analyses 
using this antibody showed that Ser280 phosphorylation of endogenous PPARα was 
increased in control mouse hearts in response to HFD consumption (Figures 2I, S3H), 
whereas there was significantly less Ser280 phosphorylation in GSK-3α cHKO mouse 
hearts (Figures 2J, S3I). Taken together, these data indicate that GSK-3α directly interacts 
with PPARα at the LBD and phosphorylates PPARα at Ser280 in the heart, and that Ser280 
phosphorylation of PPARα is increased by HFD consumption through GSK-3α activation.
GSK-3α-mediated phosphorylation enhances PPARα transcriptional activity
We examined the functional role of PPARα-Ser280 phosphorylation. First, we investigated 
whether the phosphorylation status of endogenous PPARα is altered by fatty acids through 
GSK-3α in CMs in vitro. Bovine serum albumin (BSA)-conjugated palmitic acid, a major 
saturated fatty acid in mammals, increased the nuclear localization of GSK-3α in CMs 
within 1 hour, whereas GSK-3β was located diffusely in CMs, as shown by 
immunofluorescence staining (Figure S4A). The activity of GSK-3α in the nucleus was 
increased in response to palmitic acid, as determined by immune-complex in vitro kinase 
assays of the nuclear fraction of CMs (Figure S4B). In association with the enhanced 
GSK-3α activity, PPARα-Ser280 phosphorylation in the nuclear fraction was increased by 
palmitic acid in a dose-dependent manner (Figure 3A), an effect that was suppressed in the 
presence of adenovirus-mediated knockdown of GSK-3α (adenovirus (ad)-short-hairpin 
(sh)RNA-GSK-3α) (Figures 3B, S4C). Since saturated fatty acids, such as palmitic acid, 
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monounsaturated fatty acids, such as oleic acid, and polyunsaturated fatty acids, such as 
linoleic acid, have distinct effects on metabolic diseases (Roberts et al., 2014), we examined 
the impact of unsaturated fatty acids and a fatty acids cocktail containing palmitic acid, oleic 
acid, and linoleic acid, on the GSK-3α-PPARα axis. Both oleic acid and the cocktail 
induced nuclear localization of GSK-3α and PPARα-Ser280 phosphorylation, an effect 
similar to that of palmitic acid. On the other hand, GSK-3α localization was unaffected and 
PPARα-Ser280 phosphorylation decreased in the presence of linoleic acid (Figures 3C, 
S4D–F). These results suggest that palmitic acid, oleic acid, and the fatty acids cocktail, but 
not linoleic acid, increase PPARα-Ser280 phosphorylation through GSK-3α in the CM 
nucleus in vitro.
Next, we examined the effect of Ser280-phosphorylation on PPARα transcriptional activity 
in response to palmitic acid in CMs. Knockdown of GSK-3α by ad-shRNA-GSK-3α 
abolished the palmitic acid-induced increase in PPARα activity (Figure S4G). The effect of 
PPARα-Ser280 phosphorylation on its activity was further elucidated using PPARα-WT, 
PPARα-S280A and PPARα-S280D. Whereas PPARα reporter activity dose-dependently 
increased in response to palmitic acid in PPARα-WT-transduced H9C2 cells, it was 
significantly attenuated in PPARα-S280A-transduced H9C2 cells (Figure S4H). Conversely, 
PPARα-S280D increased transcriptional activity independently of palmitic acid. These 
results suggest that GSK-3α positively regulates PPARα activity through Ser280 
phosphorylation. Since PPARγ, another PPAR isoform, is phosphorylated at Ser273 by 
ERK/CDK5 in adipose tissue in obesity (Banks et al., 2015; Choi et al., 2010), we evaluated 
the phosphorylation status of PPARγ at Ser273. Neither palmitic acid nor changes in 
GSK-3α expression altered the PPARγ-Ser273 phosphorylation level in CMs (Figures S4I, 
S4J).
To demonstrate the functional role of PPARα phosphorylation, we performed an RNA-
sequencing analysis of H9C2 cells transduced with PPARα-WT, PPARα-S280A, PPARα-
S280D or YFP as a control. The results indicated that PPARα phosphorylation induces 
global changes in gene expression (Figure 3D). Ingenuity Pathway Analysis showed that 
phosphorylation of PPARα significantly alters energy metabolism (Figure S4K). 
Furthermore, GSEAs showed that fatty acid and glycerolipid metabolism-related gene sets 
are significantly enriched in PPARα-S280D-transduced cells relative to PPARα-WT (Figure 
3E and Table S2). Gene expression changes were further examined in CMs by quantitative 
RT-PCR (Figure 3F). PPARα-S280D increased expression of genes related to fatty acid 
uptake and pyruvate dehydrogenase kinase 4 (PDK4), which inactivates the pyruvate 
dehydrogenase (PDH) complex and inhibits glucose oxidation, but genes related to β-
oxidation and mitochondrial oxidative phosphorylation were mostly either unchanged or 
decreased (Figure 3F). These results suggest that PPARα-Ser280 phosphorylation 
upregulates expression of genes involved in fatty acid uptake and storage but not utilization.
We next investigated the functional significance of PPARα phosphorylation in CMs. 
Consistent with the gene expression patterns, transduction with PPARα-S280D markedly 
enhanced uptake of BSA-palmitic acid and BSA-fatty acids cocktail into CMs compared to 
transduction with either PPARα-WT or PPARα-S280A (Figure 3G). The oxygen 
consumption rate (OCR) inhibitable with etomoxir, a Cpt1 inhibitor, was evaluated as a 
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measure of mitochondrial FAO in CMs using a Seahorse analyzer (Kim et al., 2013). Despite 
a significant increase in fatty acid uptake in CMs expressing the PPARα-S280D mutant 
compared to in those expressing PPARα-WT, FAO was not further increased in PPARα-
S280D-transduced CMs compared to in PPARα-WT-transduced CMs (Figures 3H, 3I, S4L), 
suggesting that CMs expressing PPARα-S280D accumulate more lipids than those 
expressing PPARα-WT (Figures 3J, 3K, S4M). Taken together, these results suggest that 
Ser280-phosphorylation of PPARα may shift fatty acid metabolism to fatty acid uptake and 
storage, thereby promoting lipid accumulation.
Phosphorylation of PPARα at Ser280 increases both interaction between PPARα and 
RXRα and specific DNA binding
We investigated the mechanism by which Ser280-phosphorylation enhances PPARα activity. 
YFP-tagged PPARα-S280A and -S280D mutants were both found primarily in the nucleus 
(Figure S5A), indicating that Ser280 phosphorylation does not affect the nuclear localization 
of PPARα. PPARα heterodimerizes with retinoid X receptor (RXR) and binds to the PPAR 
response element (PPRE) to activate transcription (Evans and Mangelsdorf, 2014). 
Immunoprecipitation assays showed that heterodimerization with RXRα occurs more 
efficiently in PPARα-S280D than in PPARα-WT or PPARα-S280A (Figure 4A). Although 
PPARα activity can be altered by recruitment of Sirt1 to PPARα (Oka et al., 2011), 
interaction with Sirt1 was phosphorylation-independent (Figure S5B). According to the 
three-dimensional structure of PPARα previously analyzed by X-ray crystallography (Xu et 
al., 2002), Ser280 is located on helix 3 near His440 and Lys448/449, basic residues on helix 
11 across the ligand binding pocket (Figure S5C). Thus, we predict that Ser280-
phosphorylation shortens the distance between Ser280 and His440 or Lys448/449 through 
increased electrostatic interaction, which could allow the activating function-2 (AF-2) on 
helix 12 to adopt a more stable and active conformation in an agonist-independent manner 
(Figures S5D). In fact, in vitro PPARα reporter assays showed that combined mutations 
replacing His440 and Lys448/449 with uncharged amino acids suppressed the activity of 
PPARα-S280D to a level similar to that of PPARα-WT (Figures 4B, S5E), consistent with 
the aforementioned hypothesis.
Next, we asked whether increased association of PPARα-S280D with RXRα enhances DNA 
binding. We compared the chromatin association of the PPARα-WT, PPARα-S280A, and 
PPARα-S280D alleles using chromatin immunoprecipitation assays. PPARα-S280D 
exhibited enhanced chromatin association with the promoters of genes involved in fatty acid 
uptake and transport in CMs compared to PPARα-WT, whereas PPARα-S280A exhibited 
less chromatin association than PPARα-WT (Figures 4C, S5F). However, DNA binding of 
PPARα-S280D was unchanged or decreased compared to PPARα-WT and PPARα-S280A 
when we used primers for the promoters of genes encoding mitochondrial FAO proteins 
(Figures 4D, S5F).
We further investigated the underlying mechanisms by which Ser280-phosphorylated 
PPARα preferentially stimulates fatty acid uptake-related genes rather than oxidation-related 
genes. First, we evaluated whether the binding affinity of PPARα to the PPRE is altered by 
the phosphorylation, using a double-stranded oligo pull-down assay. The oligos containing 
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the PPRE/DR1 sequences in the uptake-related gene promoters were able to pull down 
phosphorylated recombinant GST-PPARα to a greater extent than those containing the 
PPRE/DR1 sequences in the oxidation-related gene promoters (Figure 4E). On the other 
hand, the binding ability of PPARα to the PPRE sequences of the oxidation-related genes 
was higher when PPARα was not phosphorylated at Ser280 (recombinant GST-PPARα-
S280A). These results suggest that phosphorylation at Ser280 is sufficient to change the 
DNA binding preference of PPARα, even in the absence of other proteins.
In order to test whether differences in the PPRE/DR1 sequence confer a preference for 
recruiting either Ser280-phosphorylated or unphosphorylated PPARα and, consequently, 
selective control of fatty acid uptake vs oxidation, we first inspected PPRE/DR1 sequences 
in the promoters of genes upregulated by PPARα-S280D vs S280A to generate PPRE/DR1 
motifs (Figure S5G). The genes identified by the PPARα-S280D-related PPRE/DR1 motif 
were more frequently observed in the gene set identified by the fatty acid uptake-related 
PPRE/DR1 motif than in that associated with the oxidation-related PPRE/DR1 motif (Figure 
4F). These results indicate that the selective control of fatty acid uptake vs oxidation by 
PPARα-Ser280 phosphorylation is modulated at least in part by the PPRE/DR1 sequence. 
Together, these findings suggest that GSK-3α-mediated phosphorylation of PPARα at 
Ser280 increases the interaction between PPARα and RXRα and the binding of PPARα to 
specific PPREs, thereby stimulating a subset of PPARα target genes favoring fatty acid 
uptake and storage (Figure S5H).
PPARα phosphorylation is critical for HFD-induced lipid derangement in the heart
In order to demonstrate the functional significance of PPARα-Ser280 phosphorylation in the 
heart in vivo in response to HFD, we generated KI mice in which the Ser280 residue in 
PPARα was replaced with Ala (PPARα-S280A KI mice) on the C57BL/6J background, 
using homologous recombination in ES cells (Figures S6A–D). Since homozygous KI mice 
were embryonic lethal, we used heterozygous KI (het KI) mice for further characterization. 
The cardiac phenotype of the het KI mice was normal at 18 weeks of age. We first evaluated 
how the lack of PPARα-Ser280 phosphorylation affects metabolites in the heart at baseline 
by GC/MS-based metabolomic analysis. Glucose metabolites and branched-chain amino 
acids were similar in WT and het KI mice, whereas myocardial levels of free fatty acids 
were decreased in het KI mice, accompanied by decreases in fumaric acid and malic acid 
(Figures 5A, 5B, and Table S3). In order to test whether PPARα-Ser280 phosphorylation 
mediates HFD-induced lipotoxicity in the heart, het KI and WT mice were subjected to HFD 
feeding for 8 weeks. Although HFD induced Ser280 phosphorylation of PPARα in WT 
mice, the phosphorylation was reduced in het KI mice (Figure S6E). Cardiac hypertrophy 
induced by HFD was ameliorated in het KI mice (Figure 5C). Echocardiography showed a 
preserved ejection fraction in both WT and het KI mice in both the presence and absence of 
HFD (Figure S6F), while the HFD-induced diastolic dysfunction observed in WT mice was 
significantly attenuated in het KI mice (Figures 5D, S6G–J). Lipid accumulation was also 
significantly attenuated in het KI mice (Figure 5E). These results suggest that a HFD-
induced increase in PPARα-Ser280 phosphorylation plays a critical role in the development 
of lipotoxic cardiomyopathy.
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Next, we asked whether an increase in PPARα-Ser280 phosphorylation is sufficient to 
induce cardiac lipotoxicity. Either PPARα-WT or PPARα-S280D was expressed in the 
hearts of WT mice (C57BL/6J background) fed NC for 8 weeks using adeno-associated 
virus (AAV)-DJ/8-mediated gene delivery (Figure 5F). AAV-empty injection was performed 
as a control. Although no significant difference in body weight was observed among the 
groups (Figure S6K), PPARα-S280D-expressing mice exhibited cardiac hypertrophy and 
diastolic dysfunction with preserved ejection fraction (Figures 5G–J, S6L–N). Lung weight/
body weight was increased in PPARα-S280D-expressing mice, suggesting that PPARα 
phosphorylation leads to the development of HFpEF (Figure S6K). Despite an increase in 
FAO rate (Figures 5K, S6O), PPARα-S280D induced cardiac lipid accumulation to a 
markedly greater degree than PPARα-WT or AAV-empty injection, accompanied by 
increased cardiac fibrosis (Figures 5L, 5M). These results suggest that PPARα 
phosphorylation at Ser280 is sufficient to induce lipid accumulation and cardiomyopathy.
PPARα ligands inhibit GSK-3α-mediated phosphorylation of PPARα
Fenofibrate is a US Food and Drug Administration (FDA)-approved PPARα agonist. Given 
that GSK-3α interacts with and phosphorylates PPARα in the LBD, we asked whether 
fenofibrate alters the status of Ser280 phosphorylation. Interestingly, fenofibrate inhibited 
PPARα-Ser280 phosphorylation in a dose-dependent manner in CMs in the presence of 
palmitic acid or the fatty acids cocktail (Figures 6A, S7A, S7B). Another PPARα agonist, 
WY-14643, also inhibited GSK-3α-mediated PPARα-Ser280 phosphorylation in vitro, as 
well as palmitic acid-induced Ser280 phosphorylation in cultured CMs (Figures S7C, S7D).
We also tested whether fenofibrate inhibits PPARα-Ser280 phosphorylation in the heart in 
vivo and whether it ameliorates HFD-induced lipid dysregulation and cardiac dysfunction. 
Mice were fed ad libitum with HFD in the presence or absence of 0.2% (wt/wt) fenofibrate 
(Haemmerle et al., 2011) for the indicated periods (Figure S7E). Consistent with the in vitro 
results, fenofibrate treatment suppressed HFD-induced PPARα-Ser280 phosphorylation in 
the heart (Figures 6B, S7F). Systolic function was preserved in both the control and 
fenofibrate groups (Figure S7G), but fenofibrate significantly attenuated cardiac hypertrophy 
and diastolic dysfunction (Figures 6C–D, S7H–K). Although fenofibrate decreased palmitate 
oxidation in the hearts of mice fed a HFD (Figure S7L), it significantly suppressed HFD-
induced lipid accumulation in the heart (Figure 6E).
In order to test whether fenofibrate directly affects lipid metabolism in CMs, in vitro 
experiments were conducted. Fenofibrate enhanced the transcriptional activity of PPARα in 
both the absence and presence of low concentrations of palmitic acid in CMs (Figure S7M), 
confirming the role of fenofibrate as a PPARα agonist. However, fenofibrate decreased fatty 
acid-induced PPARα activation in the presence of high concentrations of palmitic acid 
(Figure S7M). Although fenofibrate suppressed PPARα reporter gene activity in response to 
a high concentration of palmitic acid in H9C2 cells transduced with PPARα-WT, it failed to 
suppress the PPARα activity in those transduced with PPARα-S280D (Figure 6F), 
suggesting that fenofibrate-induced suppression of PPARα activity in the presence of a high 
concentration of palmitic acid is mediated through suppression of PPARα-Ser280 
phosphorylation. To further demonstrate the functional alterations in lipid metabolism in 
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response to fenofibrate, CMs transduced with either PPARα-WT or PPARα-S280D were 
treated with either a low (50 μM) or high (500 μM) concentration of palmitic acid or the 
fatty acid cocktail. Seahorse analyses showed that fenofibrate suppressed the FAO rate at 
high, but not low, concentrations of fatty acids in CMs expressing PPARα-WT. However, 
fenofibrate did not affect the mitochondrial FAO rate at either low or high concentrations of 
fatty acids in CMs expressing PPARα-S280D (Figure 6G, data using the cocktail not 
shown). Similarly, although intracellular lipid accumulation, evaluated with Oil Red O 
staining, induced by a high concentration of palmitic acid was suppressed by fenofibrate in 
CMs expressing PPARα-WT, it was not affected by fenofibrate in CMs expressing PPARα-
Ser280D (Figure 6H). These results indicate that fenofibrate acts as a PPARα agonist at low 
concentrations of fatty acids but suppresses fatty acid metabolism in the presence of high 
concentrations of fatty acids, by inhibiting PPARα-Ser280 phosphorylation (Figure S7N).
Next, we examined the mechanisms by which fenofibrate decreases Ser280 phosphorylation. 
GSK-3α and YFP-tagged PPARα physically interact with one another in a palmitic acid 
concentration-dependent manner, as evaluated with pull-down assays (Figures 6I, 6J) and in 
situ proximity ligation assays (Figure 6K). Fenofibrate inhibited the interaction between 
endogenous GSK-3α and YFP-tagged PPARα in CMs. Taken together, these results suggest 
that fenofibrate negatively regulates PPARα phosphorylation in CMs by inhibiting the 
interaction between GSK-3α and PPARα, thereby suppressing PPARα activity and 
normalizing lipid derangement in the heart in the presence of high concentrations of fatty 
acid.
Finally, we examined GSK-3α activity in human failing hearts. Diabetic patients showed a 
reduction in the ratio of Ser21-phosphorylated versus total GSK-3α (Figures 6L, S7O and 
Table S4), indicating enhanced GSK-3α activity in the presence of diabetes in human hearts.
Discussion
In this study, we show that GSK-3α acts as a key kinase controlling lipid uptake and storage 
through PPARα phosphorylation. Fatty acids upregulate nuclear GSK-3α, which 
phosphorylates PPARα at Ser280, selectively stimulating transcription of genes involved in 
fatty acid uptake and storage without affecting those involved in FAO. The resultant 
imbalance between lipid uptake and consumption leads to intracellular lipid accumulation in 
metabolic syndrome. We propose that the GSK-3α-PPARα pathway is an essential mediator 
of fatty acid uptake/storage.
Ligand-independent PPARα activation through Ser280 phosphorylation
Our results suggest that Ser280 phosphorylation stimulates PPARα function independently 
of ligands. The Ser280 residue of PPARα is located in helix 3 (H3) within the LBD (Zoete 
et al., 2007). Based on the crystal structure of the PPARα LBD (Xu et al., 2002) and PPRE 
luciferase reporter assays, we predict that phosphorylation of PPARα-Ser280 enhances its 
electrostatic interaction with His440 and Lys448/449, basic residues on helix 11 (H11), 
thereby shortening the distance between H3 and H11 and allowing the adjacent helix 12 
(H12), containing AF-2, to fold up against the LBD core, creating a lid over the ligand-
binding pocket even in the absence of endogenous ligands. PPARα-Ser280 phosphorylation 
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also enhances the binding of PPARα to the PPRE in the promoters of genes involved in fatty 
acid uptake but not mitochondrial FAO. Thus, it is likely that Ser280 phosphorylation affects 
the function of PPARα through multiple mechanisms by allosterically affecting the structure 
of PPARα. This, in turn, allows Ser280-phosphorylated PPARα to selectively activate 
transcription of genes involved in fatty acid uptake and storage but not utilization; this 
selectivity is modulated at least in part by the PPRE sequence.
Previous investigations have shown that PPARγ is phosphorylated by ERK/CDK5 at Ser273 
in adipose tissues in a model of obesity (Banks et al., 2015; Choi et al., 2010). Although 
both Ser280 in PPARα and Ser273 in PPARγ are located in the LBD, there is no amino acid 
sequence homology between the regions adjacent to PPARα Ser280 and PPARγ Ser273. 
Consistently, neither fatty acids nor changes in GSK-3α activity alter the level of PPARγ-
Ser273 phosphorylation in CMs. Furthermore, although fenofibrate inhibits phosphorylation 
of PPARα at Ser280 by competing with GSK-3α, it does not inhibit phosphorylation of 
PPARγ at Ser273 (Figure S7P). More importantly, phosphorylation of PPARα at Ser280 and 
that of PPARγ at Ser273 affect distinct sets of downstream genes and exhibit distinct 
functional consequences, namely promoting fatty acid uptake and lipotoxicity in the heart 
and lipid-independent insulin resistance in adipose tissue, respectively.
GSK-3 in metabolism
GSK-3α and GSK-3β share 98% sequence similarity in their catalytic domains and 
phosphorylate some common targets in vitro. However, genetic deletion of GSK-3β in mice 
causes embryonic lethality, whereas deletion of GSK-3α does not, suggesting that GSK-3α 
and GSK-3β have distinct biological targets (Hoeflich et al., 2000). The differences in the 
amino acid sequences at the N- and C-termini confer distinct substrate specificities, and the 
difference in subcellular localization between GSK-3α and GSK-3β allows them to 
phosphorylate distinct substrates as well. Here, only GSK-3α, but not GSK-3β, translocates 
to the nucleus and interacts with PPARα in CMs in response to fatty acids. Interestingly, 
although downregulation of GSK-3α in CMs inhibited the development of cardiomyopathy 
in response to HFD consumption, downregulation of GSK-3β exacerbated HFD-induced 
cardiomyopathy. Constitutively active GSK-3α and GSK-3β regulate expression of genes 
involved in fatty acid uptake and transport in diametrically opposite directions. Elucidating 
the molecular mechanisms allowing GSK-3α and GSK-3β to exert opposite functions is 
important because none of the currently available small molecule inhibitors for GSK-3 are 
isoform specific and, thus, the beneficial effect of GSK-3α inhibition upon lipotoxic 
cardiomyopathy could be diminished or overwhelmed by the detrimental effect of GSK-3β 
inhibition. In theory, only the unique actions of GSK-3α ought to be targeted for the 
treatment of lipotoxic cardiomyopathy.
GSK-3 has recently been shown to act as a glucose sensor in B cells in the germinal center 
(Jellusova et al., 2017): GSK-3 is inactivated in the presence of abundant glucose, promoting 
cell growth and proliferation, whereas GSK-3 is activated under conditions of glucose 
deprivation, increasing glycolysis and energy production. Glucose and fatty acid metabolism 
are often reciprocally regulated. According to the Randle hypothesis, fatty acid suppresses 
glucose oxidation and induces insulin resistance in muscles through an increase in 
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intracellular citrate concentration (Randle et al., 1963). Alternatively, fatty acid negatively 
regulates glucose oxidation through DAG-mediated activation of PKCθ and IRS-1 and the 
subsequent inhibition of PI3K and GLUT4 translocation (Samuel and Shulman, 2012; 
Shulman, 2014). Our results represent another important mechanism in the heart by which 
fatty acids negatively regulate glucose oxidation: increases in fatty acids activate GSK-3α, 
which in turn upregulates PDK4 through PPARα phosphorylation. We propose that glucose 
and fatty acid metabolism may be coordinately regulated via GSK-3α in the heart and that 
the GSK-3α-PPARα axis is a major mechanism in the induction of lipotoxic 
cardiomyopathy in obesity. Since expression of GSK-3α is increased in the presence of fatty 
acids, GSK-3α and PPARα may constitute a feed-forward mechanism that not only 
contributes to myocardial energy production in the intact heart, such as during fasting, but 
also facilitates the progression of lipotoxic cardiomyopathy in metabolic syndrome. It is 
tempting to speculate that mammals, including humans, have developed this mechanism to 
allow the heart to promote fatty acid uptake and storage without stimulating FAO or 
consequent production of reactive oxygen species when fat is abundant in preparation for 
future use as a backup when fat is less available.
Bidirectional role of fibrates in cardiac lipid metabolism
Fenofibrate is a synthetic PPARα agonist that has been shown to stimulate fatty acid 
metabolism in the liver and skeletal muscle. However, the pharmacological action of 
fenofibrate in the heart remains elusive because fenofibrate fails to alter myocardial fatty 
acid metabolism in healthy human volunteers and, conversely, decreases fatty acid 
metabolism in the hearts of mice fed a HFD (Sarma et al., 2012). Here, we demonstrate that 
fenofibrate inhibits PPARα activity by blocking GSK-3α-mediated PPARα phosphorylation 
in the presence of high concentrations of fatty acids in CMs. GSK-3α is translocated into the 
nucleus in the presence of high concentrations of fatty acids, where it phosphorylates 
PPARα. Since GSK-3α and fenofibrate both bind to the PPARα LBD, fenofibrate can 
competitively inhibit the access of GSK-3α to the LBD of PPARα and inhibit Ser280 
phosphorylation.
It should be noted that the effectiveness of fenofibrate for treatment of diabetic patients 
remains controversial. Although a recent meta analysis showed that fibrates have an additive 
cardioprotective effect upon statin therapy in humans (Silverman et al., 2016), the ACCORD 
(Action to Control Cardiovascular Risk in Diabetes) trial had previously showed little or no 
effect of combination therapy with fenofibrate and simvastatin compared to simvastatin 
alone in patients with diabetes (Group et al., 2010). Given the aforementioned difficulty in 
developing an isoform-specific inhibitor for GSK-3α and the absence of an approved drug 
for lipotoxic cardiomyopathy in the clinical setting, interventions directly and selectively 
suppressing PPARα-phosphorylation at Ser280 may be more effective as a treatment for 
lipotoxic cardiomyopathy than either GSK-3 inhibitors or fenofibrate. PPARα has cell-type 
specific roles. For example, enhanced PPARα activity in muscle or liver is protective against 
diet-induced obesity or diabetes (Finck et al., 2005; Kersten et al., 1999). Furthermore, 
transcription may be regulated in a cell-type specific manner (Gosselin et al., 2014; Heinz et 
al., 2015). Thus, whether PPARα-Ser280 phosphorylation also contributes to fatty acid 
metabolism in other cell types remains to be elucidated.
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Increasing evidence suggests that the fatty acid composition of fats, including 
monounsaturated or polyunsaturated fatty acids and even-chain or odd-chain saturated fatty 
acids, the total and individual concentrations of fatty acids, and the ratio of saturated to 
unsaturated fatty acids all have distinct effects on cellular metabolism, thereby either 
promoting or preventing metabolic syndrome and cardiovascular diseases. Thus, it is 
challenging to conduct an in vitro study that faithfully mimics the fatty acid composition 
observed in HFD models in vivo. The palmitic acid concentration in human plasma ranges 
from 25 to 2500 μM, and the level of PPARα phosphorylation at Ser280 in CMs in vitro in 
response to the fatty acid concentrations we used is comparable to those in the hearts of 
mice fed either a HFD or a control diet in vivo. Therefore, the experiments conducted using 
a range of 0 to 500 μM of BSA-conjugated fatty acids in CMs in vitro closely resemble 
human lipotoxic cardiomyopathy in terms of lipid accumulation and altered cellular 
metabolism. It would be interesting to investigate the impact of additional single fatty acids 
or multiple fatty acids in combination with different ratios on the Ser280-phosphorylation 
level in the future.
Limitations of the study
The HFD we used for the in vivo study contained lard-based fats. It would be important to 
identify the key components of the fat or the ratio of each fatty acid in the blood that is 
critical for the induction of PPARα phosphorylation and the development of lipotoxic 
cardiomyopathy in vivo. In addition, the specific combination of fatty acids that would 
faithfully replicate in vivo conditions of HFD consumption for in vitro studies remains to be 
established. Although our results suggest that the PPRE/DR1 sequence plays a critical role 
in mediating the effect of Ser280 PPARα phosphorylation on the biased control of fatty acid 
metabolism, the possibility remains that the effect of Ser280 PPARα phosphorylation is 
mediated through either a DNA binding motif-independent mechanism or indirect regulation 
of fatty acid metabolism.
In summary, we demonstrate that GSK-3α acts as a central regulator of cardiac fatty acid 
metabolism by stimulating a biased PPARα transcriptional response through Ser280 
phosphorylation and consequent changes in the structure of PPARα. Activation of GSK-3α 
under conditions similar to metabolic syndrome contributes to the development of lipotoxic 
cardiomyopathy by inducing an imbalance between fatty acid uptake/storage and catabolism 
in CMs. We show that a reversal of Ser280 phosphorylation of PPARα normalizes 
lipotoxicity and cardiac dysfunction, representing a promising therapeutic intervention to 
combat lipotoxic cardiomyopathy in patients with metabolic syndrome.
STAR Methods
• Contact for Reagent and Resource Sharing
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Junichi Sadoshima (sadoshju@njms.rutgers.edu).
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• Experimental Model and Subject Details
Mice—GSK-3α heterozygous floxed mice (C57BL/6 background) were a kind gift from Dr. 
P.S. Klein (University of Pennsylvania). GSK-3β floxed mice (C57BL/6 background) were a 
kind gift from Dr. C.J. Phiel (He et al., 2010). GSK-3α and β knock-in mice were a kind gift 
from Dr. D.R. Alessi (University of Dundee). Cardiomyocyte-specific deletion of GSK-3α 
or GSK-3β was obtained by crossing the mice with α-myosin heavy chain promoter-driven 
heterozygous Cre mice (a kind gift from Dr. M.D. Schneider). Cardiomyocyte-specific Tg-
FLAG-PPARα (α-myosin heavy chain promoter) mice were a kind gift from Dr. D. Kelly. 
Male C57BL/6J ob/ob mice and male C57BL/6J wild-type mice were purchased from 
Jackson Labs at 5–6 weeks of age. For diet-induced obesity, male 5 to 6-week-old animals 
were fed a high-fat (60%) diet (Research Diets, D12492). The PPARα ligand, fenofibrate 
(Sigma-Aldrich), was provided via ad libitum feeding with a high-fat diet containing 0.2% 
(wt/wt) fenofibrate (custom diet purchased from Research Diets) for the indicated periods 
(Haemmerle et al., 2011). For cardiac insulin resistance tests, mice were fasted for 4 hours, 
followed by intraperitoneal injection of 0.75 U/kg body weight insulin. Fifteen minutes after 
insulin injection, the hearts were harvested to evaluate phosphorylation of Akt by 
immunoblot. For intraperitoneal glucose tolerance tests in HFD-fed mice, mice were fasted 
for six hours and body weight and fasting glucose level from a small tail clip were measured. 
Glucose (1 mg/g body weight) was injected intraperitoneally and blood glucose values were 
obtained at 15, 30, 45, 60, 90, and 120 mins. Mice were housed in a temperature-controlled 
environment within a range of 21–23 °C with 12-hour light/dark cycles and were fed an 
indicated diet. We used age-matched male mice in all animal experiments. All protocols 
concerning the use of animals were approved by the Institutional Animal Care and Use 
Committee at New Jersey Medical School, Rutgers University.
Gene targeting mouse—PPARα genomic DNA was isolated from BAC clone (RP24–
545F24) to construct the PPARα S280A KI targeting vector. PCR-based site-directed 
mutagenesis was performed to introduce a single mutation of T to G in codon 280 in exon 8 
of PPARα to change codon 280 from Ser to Ala. A pGK neo cassette flanked by two FRT 
sites (a kind gift from Dr. Takeda, Osaka University) was inserted into intron 8 for selection 
of the targeted allele. Diphtheria Toxin A fragment was used for negative selection. The 
DNA sequences used for constructing the targeting vector, including introns 7 and 8 and 
exon 8, were confirmed by DNA sequencing. The targeting vectors were linearized with 
PmeI and subsequently electroporated into ES cells. G418-resistant ES clones were screened 
for homologous recombination by long range PCR using the primers listed in Table S5 with 
the Expand Long Template PCR system (Roche #11681842001). Three positive clones were 
identified out of 288 clones. Homologous recombinant ES clones were microinjected into 
blastocysts from C57BL/6J mice and transferred into pseudo-pregnant recipients to generate 
male chimeras. The chimeric male mice resulting from the microinjection were bred with 
C57BL/6J female mice to generate germline-transmitted heterozygous S280A KI mice. PCR 
analysis was performed on tail DNA from offspring. Sequence analysis was performed on 
PCR products to verify the presence of the mutations using standard procedures. The mutant 
offspring were backcrossed into the C57BL/6J background.
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GSK-3α flox/flox mice were generated in Dr. Peter S. Klein’s laboratory (University of 
Pennsylvania, Philadelphia). Briefly, a conventional targeting vector with neomycin 
resistance and TK was generated to insert loxP sites on either side of exon 2 in the Gsk3a 
gene. The neomycin resistance cassette, inserted downstream of exon 2, was also flanked by 
FRT sites. The construct was electroporated into ES cells derived from C57BL/6 mice and 
positive and negative selection was used to isolate positive clones, which were then screened 
by PCR for the correct insertion and confirmed by Southern blot. Cre-mediated excision 
removes exon 2, which encodes an essential portion of the catalytic domain, to generate a 
null allele.
Human samples from explanted hearts—The samples from explanted hearts used in 
this study were obtained from 14 non-diabetic (mean age 52.0 ± 11.8 years; 13 males) and 7 
diabetic (mean age 50.4 ± 11.6 years; 6 males) patients who had received heart transplants at 
the Taipei Veterans General Hospital. The study was approved by the Ethics Committee of 
Taipei Veterans General Hospital, and all patients or their families expressed their 
willingness to participate through an informed consent form. Myocardial samples from near 
the mitral annulus were obtained at the time of therapeutic transplantation. Immediately after 
tissue procurement, the samples for biochemical studies were stored in liquid nitrogen and 
kept at −80°C.
Cell line—H9C2 cells were maintained at 37°C with 5% CO2 in Dulbecco’s modified 
Eagle’s medium/Nutrient Mixture F-12 supplemented with 10% fetal bovine serum. 
Information on the sex is not available.
Primary Rat Neonatal Cardiomyocytes—Primary cultures of ventricular CMs were 
prepared from 1-day-old Crl:(WI)BR-Wistar rats (both sexes) (Harlan Laboratories, 
Somerville) and maintained in culture. A cardiomyocyte-rich fraction was obtained by 
centrifugation through a discontinuous Percoll gradient. CMs were cultured in complete 
medium containing Dulbecco’s modified Eagle’s medium/F-12 supplemented with 5% horse 
serum, 4 μg/ml transferrin, 0.7 ng/ml sodium selenite, 2 g/l bovine serum albumin (fraction 
V), 3 mM pyruvate, 15 mM Hepes pH 7.1, 100 μM ascorbate, 100 mg/l ampicillin, 5 mg/l 
linoleic acid, and 100 μM 5-bromo-2’-deoxyuridine (Sigma). Culture dishes were coated 
with 0.3% gelatin or 2% gelatin for immunofluorescence staining on chamber slides.
• Method Details
Antibodies and reagents—The following commercial antibodies were used at the 
indicated dilutions: phospho-GSK-3α (Ser21) (36E9) (1:1,000), total GSK-3α (D80E6, for 
WB) (1:2,000), total GSK-3α (D80D1, for IF) (1:100), total GSK-3α/β (D75D3) (1:4,000), 
phospho-GSK-3α/β (1:2,000), histone H3 (1:5,000), GAPDH (14C10) (1:5,000), GFP 
(D5.1, for IF) (1:500), and secondary antibodies (anti-mouse or rabbit IgG) conjugated with 
horseradish peroxidase (1:4,000) (Cell Signaling); secondary antibodies (anti-mouse or 
rabbit IgG) conjugated with Alexa Fluor 488 or 555 (1:100) (Life Technologies); GFP-
magnetic beads (Fisher/MBL); total PPARα (1:3,000) (Cayman Chemical); RXRα (D-20) 
(1:4,000) (Santa Cruz); α-actinin (1:4,000) (sarcomeric) (Sigma-Aldrich). For detection of 
phosphorylation of PPARα at Ser280, a polyclonal phosphorylation-specific antibody was 
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generated by immunizing rabbits with a phospho-peptide corresponding to residues 
surrounding Ser280 of PPARα (1:1,000). Antibodies were diluted in either 5% (w/v) BSA 
or 5% (w/v) non-fat dry milk in 1xTBS/0.5%Tween 20, depending on the level of 
background intensity. The following reagents were used: WY-14643 and fenofibrate (R & D 
Systems, Tocris for in vitro experiments); Palmitic acid, Duolink In Situ PLA, and Etomoxir 
(Sigma-Aldrich).
Adenovirus constructs—Recombinant adenovirus vectors for overexpression and short 
hairpin RNA-mediated gene silencing were constructed, propagated and titered as previously 
described (Oka et al., 2011). pBHGloxΔE1,3Cre plasmid was co-transfected with the 
pDC316 shuttle vector (Microbix) or pDCSilencer (Microbix) containing YFP-PPARα-WT, 
YFP-PPARα-mutants, or GSK-3α targeting sequences into HEK293 cells using 
Lipofectamine 2000 (Life Technologies). The cDNA of mouse PPARα was amplified using 
pDC316-PPARα (Oka et al., 2011) as a template and ligated into pDC316-YFP-N terminal 
vector (Maejima et al., 2013). The shuttle vector for the short hairpin sequence of rat 
GSK-3α was generated by insertion of a complementary hairpin sequence of rat GSK-3α 
(see key resources table) into pDCSilencer (Microbix). The luciferase reporter plasmid 
(pPPRE-tk-luc) was a kind gift from Dr. Ronald Evans at the Salk Institute. Mutations were 
performed by site directed mutagenesis. Adenovirus vectors harboring LacZ (Ad-LacZ) and 
sh-Scramble (Ad-shScr) were used as controls. The total MOI of adenovirus was kept 
constant using LacZ or Scramble virus.
Adeno-associated virus—The recombinant adeno-associated virus (AAV) vectors used 
to generate AAV-DJ/8-PPARα-WT or S280D were constructed by cloning the cDNA of 
PPARα-WT or S280D (mouse) from the pDC316-YFP-PPARα-WT or S280D vector into 
the pAAV-MCS expression vector (Cell Biolabs, Inc, #VPK-410) downstream of the CMV 
promoter with BamHI and SalI. 293AAVcells (Cell Biolabs, Inc.) were co-transfected with 
the recombinant AAV vectors, pAAV-DJ/8 vector, and helper plasmid in a 1:1:1 ratio using 
polyethylenimine (PEI) at the AAV core, Department of Cell Biology and Molecular 
Medicine, New Jersey Medical School, Rutgers University, Newark, NJ (Grimm et al., 
2008). The recombinant AAV produced was purified by the iodixanol gradient/ultra-
centrifugation method, and the AAV fraction was concentrated using a VIVASPIN 20 
concentrator (100 kDa cut-off, Sartorius, Germany). The virus titer was determined using the 
Cell Biolabs AAV quantitation kit (Cat. # VPK-145). To administer recombinant AAVs, 
doses of 2×1011 vector genome per mouse were injected intravenously via the jugular vein 
of C57BL/6J wild-type mice.
Recombinant proteins—The bacterial expression vectors for GST-fused PPARα-full 
length and -truncates (T1–5) were generated by insertion of mouse PPARα cDNA amplified 
by PCR into the pCold-GST-vector. The BL21 E. coli strain was transformed with pCold-
GST-PPARα-full length or truncates. The E. coli was grown in 3 ml LB medium containing 
ampicillin overnight at 37°C, and then transferred to 250 ml LB medium containing 
ampicillin. Protein expression was induced by addition of 1 mM isopropylthio-β-
galactoside. After overnight culture at 15°C, the E. coli were lysed in lysis buffer (1% Triton 
X-100 and 1 mM DTT in PBS) with sonication. The lysate was incubated with 0.5 ml 
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Glutathione-sepharose 4B (GE Healthcare) for 1 hour at 4°C. The sepharose was washed 3 
times with 5 ml lysis buffer, and then suspended with 1 ml cleavage buffer (20 mM Tris pH 
7, 150 mM NaCl, 1 mM DTT).
In vitro kinase assay—Recombinant active GSK-3α was purchased from Millipore. 
Recombinant PPARα-LBD (human) was purchased from Cayman Chemical. GST-tagged 
full-length PPARα protein was generated using the pCold-GST-vector. Recombinant active 
GSK-3α (10 ng) was incubated with recombinant GST-full length-PPARα (1 μg) or 
PPARα-LBD (1 μg) in a kinase buffer (50 mM HEPES (pH 7.4), 15 mM MgCl2 and 200 μM 
sodium vanadate containing 100 μM ATP in the presence or absence of 10 μCi [γ−32P]ATP 
per reaction) at 30°C for 15 minutes. Phosphorylated proteins were separated by SDS-PAGE 
and analyzed by autoradiography or immunoblot.
Mass spectrometry—A kinase reaction was performed using recombinant GST-tagged 
PPARα and GSK-3α proteins. Phosphorylated proteins were separated by SDS-PAGE and 
stained with Coomassie Brilliant Blue. The gel band of interest was excised for in-gel 
trypsin digestion. The resulting peptides were subjected to LC-MS/MS analysis on an 
Ultimate 3000 (Dionex, Sunnyvale, CA, USA) LC system coupled with an Orbitrap Velos 
tandem mass spectrometry instrument (Thermo Fisher Scientific). The MS spectra were 
acquired in positive mode with a spray voltage of 2 kV and a capillary temperature of 275ºC. 
The Lock Mass feature was used for accurate mass measurement. The automatic gain 
control (AGC) target was set to 1.0E+6 for full scan in the Orbitrap mass analyzer and 3.0E
+4 for MS/MS scans in the ion trap mass analyzer. The precursor was selected within a 2 
m/z isolation window and fragmented using collision-induced dissociation (CID) 
fragmentation. The MS/MS spectra were searched against the Swissprot mouse database 
with an MS error tolerance of 10 ppm and an MS/MS error tolerance of 0.5 Da. Methionine 
oxidation, cysteine carbamidomethylation (IAM) and serine/threonine phosphorylation were 
set as variable modifications. One % false discovery rate (FDR) was used for both protein 
and peptide identification.
RNA-Seq library preparation, sequencing and data analysis—Total RNA was 
isolated from H9C2 cells transduced with the indicated plasmid using TRIzol (Invitrogen). 
Isolated RNA was first checked for integrity on an Agilent Bioanalyzer 2100; samples with 
RNA integrity number (RIN) >7.0 were used for subsequent processing. Total RNA was 
subjected to two rounds of poly(A) selection using oligo-d(T)25 magnetic beads (New 
England Biolabs). A paired-end (strand specific) cDNA library was prepared using the NEB 
Next Ultra-directional RNA-Seq protocol. Briefly, poly(A)+ RNA was fragmented by 
heating at 94°C for 10 minutes followed by reverse transcription and second strand cDNA 
synthesis using the reagents provided in the NEB Next kit. End-repaired cDNA was then 
ligated with double stranded DNA adapters, followed by purification of ligated DNA with 
AmpureXP beads. cDNA was then amplified by PCR for 15 cycles with a universal forward 
primer and a reverse primer with bar code. The sequencing of the cDNA libraries was 
performed on the Illumina HiSeq 2500 platform (Illumina, San Diego, CA) using the single-
read 1×50 cycles configuration. The raw reads files have been deposited in the NCBI Gene 
Expression Omnibus.
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CLC Genomics Workbench version 8.5 (http://www.clcbio.com/products/clc-genomics-
workbench/; Qiagen) was used for RNA-seq analysis. De-multiplexed fastq files from RNA-
Seq libraries were imported into the CLC software. Adaptor sequences and bases with low 
quality were trimmed and reads were mapped to a reference genome, Rattus norvegicus 
(assembly Rnor_6.0). Read mapping was carried out with the RNA-Seq Analysis Tool of 
CLC Genomics Workbench. RPKM values were calculated for each gene to quantify 
absolute expression. Statistical analysis of differentially expressed genes was carried out 
with the Empirical analysis of Digital Gene Expression data tool in CLC Genomic 
Workbench. Functional Pathway analysis of PPARα-Ser280 phosphorylation-regulated 
genes (SD vs SA) was performed using IPA pathway analysis software (QIAGEN). 
Expression patterns of regulated genes were graphically represented in a heat map. 
Hierarchical clustering was performed to group genes with similar features in the expression 
prolife. The clustering and visualization were carried out using the MultiExperiment Viewer 
(MeV).
The following publicly available microarray datasets were used: OB/OB (GSE16790), 
DB/DB (GSE36875), and streptozotocin-induced type I diabetic model (GSE5606). Raw 
intensity values were normalized using the Robust Multi-array Average (RMA) method on 
R. A p value less than 0.05 in the empirical analysis was considered statistically significant. 
Normalized expression data were also analyzed with GSEA v2.0.13 software using the JAVA 
program (Broad Institute, Cambridge, MA). All gene sets were obtained from the Molecular 
Signatures Database v4.0 distributed on the GSEA Web site.
Quantitative RT-PCR—Total RNA was prepared from mouse hearts and CMs using 
TRIzol (Invitrogen). cDNA was generated using 300 ng total RNA and SuperScript III 
Reverse Transcriptase (ThermoFisher). Using Maxima SYBR Green qPCR master mix 
(Fermentas), real-time RT-PCR was performed under the following conditions: 94°C for 10 
minutes; 40 cycles of 94°C for 15 seconds, 58°C for 30 seconds, 72°C for 30 seconds; and a 
final elongation at 72°C for 15 minutes. Relative mRNA expression was determined by the 
ΔΔ-Ct method normalized to the ribosomal RNA (18S) level. Primer sequences are shown in 
Table S5.
Metabolomics analysis—Myocardial tissue samples were harvested from heterozygous 
PPARα-S280A KI and littermate control mice at the age of 18 to 20 weeks (n=5). 
Untargeted screening of the metabolome in ventricular tissue was performed using GC/MS 
at the University of Utah Metabolomics Core Facility. The freeze-clamped tissue samples 
(~15 mg) were homogenized in the extraction solution (methanol/water (8:1) with amino-
acid standards and D4 succinate) using a ceramic bead tube kit (MO BIO Laboratories, Inc., 
Carlsbad, CA) and Bead Ruptor (Omni International, Kennesaw, GA). After incubation for 2 
hours at −20°C followed by centrifugation at 13,000g at 4°C for 10 minutes, the extraction 
samples were dried using a Speed-vac (MiVac Duo, Barnstead/Genevac Inc., Gardiner, NY) 
overnight and suspended in 40 μl of 40 mg/ml O-methoxylamine hydrochloride (MOX) in 
pyridine. GC/MS analysis was performed with a Waters GCT Premier mass spectrometer 
fitted with an Agilent 6890 gas chromatograph and a Gerstel MPS2 autosampler. A 30 m 
Phenomenex ZB5–5 MSi column with a 5 m long guard column was employed for 
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chromatographic separation. Data were collected by MassLynx 4.1. Initial analysis of known 
metabolites was performed using QuanLynx with data transfer to Excel. Peak picking was 
performed using MarkerLynx with data mining performed using SIMCA-P ver. 12.0.1. The 
values were normalized by wet tissue weight. Bioinformatic analysis of the metabolomic 
data was carried out using Metaboanalyst 3.0 software, including the generation of heat 
maps. Differences in the abundance of individual metabolites were determined using a 
Student’s t-test (2 tails, unpaired comparison). A value of p<0.05 was considered 
statistically significant. Data are given as mean ± s.e.m.
Immunoblotting—CM lysates and heart homogenates were prepared in RIPA buffer 
containing protease and phosphatase inhibitors (Sigma-Aldrich). Lysates were centrifuged at 
13,200 r.p.m. at 4°C for 15 minutes. Total protein lysates (10–30 μg) were incubated with 
SDS sample buffer (final concentration: 100 mM Tris pH 6.8, 2% SDS, 5% glycerol, 2.5% 
2-mercaptoethanol, and 0.05% bromophenol blue) at 95°C for 5 minutes. The denatured 
protein samples were separated by SDS-PAGE, transferred to polyvinylidene difluoride 
membranes by wet electrotransfer, and probed with primary antibodies.
Subcellular fractionation—Cultured neonatal rat CMs were washed with PBS and 
collected with ice-cold PBS, followed by centrifugation at 600g for 5 minutes. CMs were 
then resuspended in hypotonic lysis buffer (10 mM K-HEPES pH 7.9, 1.5 mM MgCl2, 10 
mM KCl, 0.1 mM EGTA, 0.1 mM EDTA, 1% IGEPAL, 1% Phosphatase Inhibitor Cocktail, 
and 1% Protease Inhibitor Cocktail) and were incubated for 15 minutes on ice with 
intermittent pipetting. Whole-cell lysates were centrifuged at 1200g for 5 minutes. The 
supernatant was collected for the cytosolic fraction, and the pellets were resuspended in lysis 
buffer (20 mM K-HEPES, 25% Glycerol, 0.45 M NaCl, 1.5 mM MgCl2, 1 mM EGTA, 1 
mM EDTA, 1% Phosphatase Inhibitor Cocktail, and 1% Protease Inhibitor Cocktail) and 
were incubated for 15 minutes on ice with intermittent pipetting. The total homogenate was 
centrifuged at 13,000rpm for 10 minutes to collect the nuclear fraction. The pelleted nuclei 
were resuspended in lysis buffer and protein content was determined for all fractions. The 
nuclear fraction from mouse hearts was prepared with NE-PER Extraction Reagent (Thermo 
Scientific).
Immunoprecipitation—CMs or heart samples were lysed with lysis buffer containing 50 
mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton-X 100, 1% Sodium Deoxycholate, Protease 
Inhibitor Cocktail (Sigma), and Phosphatase Inhibitor Cocktail (Sigma). Primary antibody 
was covalently immobilized on protein A/G agarose using the Pierce Crosslink 
Immunoprecipitation Kit according to the manufacturer’s instructions (Thermo Scientific). 
Samples were incubated with immobilized antibody beads for at least 2 hours at 4°C. After 
immunoprecipitation, the samples were washed with TBS five times. They were then eluted 
with glycine-HCl (0.1 M, pH 3.5) and the immunoprecipitates were subjected to 
immunoblotting using specific primary antibodies and a conformation-specific secondary 
antibody that recognizes only native IgG (Cell Signaling).
Immune complex in vitro kinase assay—The nuclear fraction was obtained as 
described in the section on subcellular fractionation. GSK-3α was immunoprecipitated as 
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described in the section on immunoprecipitation. Immunoprecipitated endogenous GSK-3α 
protein or recombinant GSK-3α protein was incubated with recombinant GST-β-catenin or 
GST alone as a control in kinase buffer as described in the section on in vitro kinase assays, 
then incubated with 5xSDS sample buffer at 95°C for 5 minutes, followed by SDS-PAGE. 
Proteins were detected by immunoblot using pβ-catenin antibody.
In vitro binding assays—Recombinant GST-fused proteins in a slurry of glutathione 
sepharose were incubated with CM lysates, recombinant GSK-3α, or recombinant GSK-3β 
in lysis buffer containing 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton-X 100, 1% 
Sodium Deoxycholate, Protease Inhibitor Cocktail (Sigma), and Phosphatase Inhibitor 
Cocktail (Sigma) with rotation for 1 hour at 4°C, followed by pull-down with glutathione-
sepharose. After washing five times with PBS, proteins were eluted with 5xSDS sample 
buffer, followed by SDS-PAGE and immunoblots.
Reporter gene assay—PPRE reporter gene activity in rat neonatal CMs was measured 
with a luciferase assay system (Promega). Cardiomyocytes were transfected with 3xPPRE 
luciferase reporter plasmids (0.2 μg) overnight (24 well plate) using LipofectAmine 2000 
(Invitrogen). The PPRE reporter gene assay was performed after 9 hours of palmitic acid 
treatment. CMs were lysed with 50 μl Reporter lysis buffer (24 wells each). The 
luminescence reaction was started by adding 5 μl lysate to 50 μl Reaction buffer, and 
luminescence was measured for 10 seconds using an OPTOCOMP I luminometer (MGM 
Instruments, Inc.). The luminescence was normalized by protein content measured by 
protein assay kit (BioRad). H9C2 cells were transfected in bulk with 7 μg of total DNA 
consisting of 6.4 μg of 3xPPRE-luciferase reporter and 0.6 μg of PPARα in a pDC316 vector 
using FuGene 6 (Roche) at a lipid to DNA ratio of 3:1. Following 18 hours of transfection, 
cells were trypsinized and replated into 96 well plates (Perkin Elmer) and incubated for 4 
hours at 37°C and 5% CO2. Palmitic acid and PPARα ligands were added and the cells were 
further incubated for 9 hours. Luciferase levels were assayed using BriteLite Plus (Perkin 
Elmer) and read using a multi-label plate reader (Perkin Elmer).
Chromatin immunoprecipitation (ChIP) assay—CMs were transduced with Ad-YFP-
PPARα-WT or -mutants or Ad-YFP as a control (10 cm dish). Two days after transduction, 
CMs were fixed to cross-link protein-DNA complexes for 10 minutes with 1% formaldehyde 
in complete medium containing Dulbecco’s modified Eagle’s medium/F-12 supplemented 
with 5% horse serum, 4 μg/ml transferrin, 0.7 ng/ml sodium selenite, 2 g/l bovine serum 
albumin (fraction V), 3 mM pyruvate, 15 mM Hepes pH 7.1, 100 μM ascorbate, 100 mg/l 
ampicillin, 5 mg/l linoleic acid, and 100 μM 5-bromo-2’-deoxyuridine (Sigma) at room 
temperature. Cross-linking was stopped by addition of 1 M Glycine to a final concentration 
of 125 mM for 5 minutes. CMs were washed twice with ice-cold PBS and the nuclear 
fraction was collected as described in the section on subcellular fractionation. The nuclear 
fractions were subjected to ultrasonic treatment with a Diagenode Bioruptor to generate 200-
to 1000-bp DNA fragments and were then diluted 10-fold with dilution buffer [16.7 mM 
Tris-HCl pH 8.1, 1.2 mM EDTA, 0.01% SDS, 1.1% Triton X-100, protease inhibitor 
cocktail]. After the addition of EDTA to a final concentration of 0.1 mM, the digested 
sample was centrifuged at 15,000g for 10 min at 4°C and the resulting supernatant was 
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incubated with rotation at 4°C overnight with anti-GFP-YFP conjugated magnetic beads. 
The immunoprecipitated chromatin was washed five times with low salt buffer [20 mM Tris-
HCl, 150 mM NaCl, 2 mM EDTA, 1% Triton X, and 0.1% SDS] and high salt buffer [20 
mM Tris-HCl, 500 mM NaCl, 2 mM EDTA, 1% Triton X, and 0.1% SDS], followed by 
elution with elution buffer [0.1 M NaHCO3 and 1% SDS]. Protein-DNA cross-links were 
reversed by incubation overnight at 65°C with 1% SDS in Tris-EDTA buffer, followed by 
incubation at 45°C for 1 hour with proteinase K and RNase A. DNA fragments were purified 
with a Qiaquick PCR Purification kit (QIAGEN). The DNA was then used as a template for 
RT-PCR analysis. The PCR primer sequences are listed in Table S5.
In vitro oligo pull-down assay—Recombinant Glutathione S-transferase (GST)-fused 
PPARα-WT or PPARα-S280A proteins were purified from the BL21 E. coli strain 
transformed with pCold-GST backbone plasmids. The recombinant proteins were subjected 
to in vitro kinase assays using recombinant GSK-3α protein, followed by purification with 
Glutathione-sepharose 4B (GE Healthcare), washing with binding buffer 3 times and 
resuspension with 150 μl binding buffer [10 mM Hepes pH 7.9, 2.5 mM MgCl2, 50 mM 
KCl, 150 mM NaCl, 5% glycerol, 1 mM DTT, 0.1% IGEPAL CA-630]. The recombinant 
proteins were incubated with biotin-labeled double-stranded DNAs with streptavidin-beads 
at 4°C for 2 hours. The recovered proteins were washed 3 times and resolved by SDS-PAGE. 
The sequences of the double-stranded DNAs are listed in Table 5.
Generation of the PPRE/DR1 sequence logos—We searched the PPRE/DR1 
sequences in the promoters of genes upregulated in PPARα-S280D- or-S280A-transduced 
H9C2 cells (SD vs SA, fold change > 1.5 using the RNAseq data) and in the promoters of 
fatty acid uptake- or oxidation-related genes using the MEME software (Multiple EM for 
Motif Elicitation Version 5.0.2, The MEME SUITE). The sequence of the PPRE element 
containing direct repeats of the AGGTCA half-site separated by one base pair (canonical 
PPRE/DR1) together with the upstream and downstream three base pairs 
(nnnAGGTCAnAGGTCAnnn) was used as an input motif for matches to the DR1 sequences 
in the promoters with a threshold of p < 1.0E-4. Based on previously published reports, the 
following genes were assigned for fatty acid uptake/transport or oxidation-related genes in 
the heart: Slc27a1, Lpl, Acsl1, Cd36, Fabp3, and Fabp4 for uptake/transport; Acadvl, 
Acadm, Acadl, Acads, Acadsb, Hadha, Hadhb, Echs1, and Hadh for oxidation. Using the 
identified sequences, we generated the PPRE/DR1 sequence logos with the MEME 
software. Finally, we identified rat genes containing each PPRE/DR1 motif in their 
promoters with a threshold of p < 1.0E-5 using MEME. The 5000 bp promoter sequences in 
the rat genome were obtained using the UCSC Genome Browser (RGSC 6.0/m6). Genes 
containing both fatty acid uptake- and oxidation-related motifs were excluded. Genes 
containing both PPARα-S280D- and -S280A-related motif were excluded as well. The 
remaining genes were plotted in a Venn Diagram using Bioinformatics & Evolutionary 
Genomics website.
Echocardiography—Mice were anesthetized using 12 μl/g body weight of 2.5% avertin 
(Sigma-Aldrich), and echocardiography was performed using ultrasound (Vivid 7, GE 
Healthcare). A 13-MHz linear ultrasound transducer was used. Mice were subjected to 2-
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dimension guided M-mode measurements of LV internal diameter to measure systolic 
function and wall thickness, and transmitral inflow Doppler echocardiography in apical 4-
chamber view to measure deceleration time of early filling of mitral inflow. Both were taken 
from at least three beats and averaged. LV ejection fraction was calculated as follows: 
Ejection fraction = [(LVEDD)3 – (LVESD)3]/(LVEDD)3 × 100. For all mouse experiments, 
data analysis was conducted in a blinded manner.
Pressure-volume (PV) loop analysis—Mice were anesthetized with pentobarbital (60 
mg/kg, intraperitoneal injection) and subjected to PV loop analyses to measure diastolic and 
systolic cardiac function. The right common carotid artery was surgically isolated and 
clamped proximally and distally. A small incision (5–10 mm) was made on the carotid 
artery, and a 1.4-French pressure-conductance catheter (Millar Instruments) was inserted in 
the vessel and introduced into the left ventricle. The PV relation and hemodynamics were 
continuously recorded. After stabilization, the end-systolic PV relation and its slope and the 
end-diastolic PV relation and its slope were obtained by intermittent occlusion of the inferior 
vena cava.
Metabolic assay—The oxygen consumption rate (OCR, pmol/min) in cultured CMs was 
determined using a Seahorse XF24 or XF96 Extracellular Flux Analyzer (Seahorse 
Bioscience) according to the Installation and Operation Manual from Seahorse Bioscience. 
CMs were plated at a density of 200,000 cells/well in 24-well Seahorse assay plates or at a 
density of 50,000 cells/well in 96-well Seahorse assay plates, followed by transduction with 
Ad-PPARα-WT or Ad-PPARα-mutants for 34 hours and additional incubation with 500 μM 
BSA-conjugated fatty acids for 14 hours prior to measurement. One hour prior to the 
beginning of measurements, the medium was replaced with XF assay medium containing 
unbuffered DMEM, 5.5 mM glucose, and 0.5 mM carnitine, and CMs were incubated for 1 
hour in a 37°C incubator without CO2. Etomoxir (100 μM), a specific Cpt-1 inhibitor, was 
added to assess the degree of FAO (Kim et al., 2013).
Adult CMs isolation and metabolic assay—Adult CMs were isolated as described 
previously with a modification (Ackers-Johnson et al., 2016). Briefly, the heart of a male 
mouse was perfused with 12 ml EDTA buffer [130 mM NaCl, 5 mM KCl, 0.5 mM 
NaH2PO4, 10 mM HEPES, 10 mM Glucose, 10 mM BDM, 10 mM Taurine, 5 mM EDTA] 
to stop the beating of the heart. Digestion was achieved using 30 ml perfusion buffer [130 
mM NaCl, 5 mM KCl, 0.5 mM NaH2PO4, 10 mM HEPES, 10 mM Glucose, 10 mM BDM, 
10 mM Taurine, 1 mM MgCl2] containing Collagenase type II (0.5mg/ml) and Protease XIV 
(0.05mg/ml). Cellular dissociation was stopped by addition of 5 ml Perfusion buffer 
containing 5% FBS and 500 μM BSA-conjugated fatty acid cocktail (palmitic acid: oleic 
acid: linoleic acid = 2:1:1 and BSA: fatty acid = 1:5). CMs and non-CMs were separated by 
4 sequential rounds of gravity settling with calcium reintroduction medium containing 500 
μM BSA-conjugated fatty acid cocktail. Adult CMs were plated at a density of 200 cells/
well in 96-well Seahorse assay plates with XF assay medium, containing 5.5 mM glucose, 
500 μM BSA-conjugated fatty acid cocktail, 10 mM BDM and 0.5 mM carnitine. Adult 
CMs were incubated in a 37°C incubator with CO2 for 30 minutes and without CO2 for 30 
Nakamura et al. Page 23
Cell Metab. Author manuscript; available in PMC 2020 May 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
minutes prior to measurement. The FAO rate was determined by Etomoxir (250 μM)-
inhibitable OCR using a Seahorse XF96 Extracellular Flux Analyzer (Seahorse Bioscience).
Fatty acid oxidation—Fatty acid β-oxidation was measured using heart homogenates as 
described previously (Watanabe et al., 2000). The left ventricle (LV) of a fresh heart was 
washed with PBS, weighed and homogenized in four volumes of homogenate buffer [0.25 M 
Sucrose, 1 mM EDTA] per LV weight (mg). Forty μl of the heart homogenate was dispensed 
per tube and centrifuged at 800g for 1.5 minutes and the precipitates were incubated with 
200 μl of Reaction buffer [10 mM Hepes pH 7.4, 150 mM KCl, 0.1 mM EDTA, 1 mM 
K2HPO4, 10 mM MgCl2, 1 mM Malate, 10 mM Glucose, 1 μCi [9,10-3H] palmitic acid and 
50 μM of unlabeled palmitic acid, both bound to BSA at the molecular ratio of 1:3.7 (BSA : 
fatty acid)] at 37°C for 10 minutes. The reaction was stopped by the addition of 1 ml 
chloroform/methanol (2:1) and the samples were mixed well. The samples were kept at 
−20°C for 4 hours and centrifuged at 12,000g at room temperature for 10 minutes. The 
supernatants containing 3H2O were mixed with 4 ml scintillation fluid and the radioactivity 
was measured with a scintillation counter.
Fatty acid uptake in vitro—Rat neonatal CMs were transduced with adenovirus 
harboring PPARα-WT, PPARα-S280A, PPARα-S280D or YFP alone. Two days after 
transduction, CMs were incubated in CM culture medium containing 500 μM unlabeled 
BSA-conjugated palmitic acid or 500 μM unlabeled BSA-conjugated fatty acid cocktail 
(palmitic acid, oleic acid, and linoleic acid (2:1:1 ratio)) with 1 μCi/ml of [9,10-3H(N)]-
palmitic acid alone or 1 μCi/ml of combined [9,10-3H(N)]-palmitic acid and [9,10-3H(N)]-
oleic acid and 1.25% BSA for 10 minutes (Liu et al., 2011). After washing CMs with ice-
cold PBS four times, CMs were harvested with trypsin-EDTA and centrifuged at 800g at 
room temperature for 3 minutes. The pellet was resuspended with 1 ml PBS and centrifuged 
at 800g at room temperature for 3 minutes again. CMs were lysed with 1 ml of 0.5 M NaOH 
and neutralized with 6 M HCl. The radioactivity was measured with a scintillation counter.
Palmitate uptake into the heart in vivo—In vivo palmitic acid uptake was measured as 
previously described with modifications (Khan et al., 2013). Palmitic acid [9, 10-3H(N)]- 5 
mCi (PerkinElmer, NET043005MC) was complexed with 6% BSA at 37°C. Male GSK-3α 
S21A KI and control mice were fasted for 2 hours and were intravenously administered the 
labeled BSA-conjugated palmitic acid and 400 μM of unlabeled BSA-conjugated palmitic 
acid via the femoral vein with ~106 counts and euthanized 5 minutes post-injection. Blood 
samples collected 2 minutes after the injection were used for normalization. The heart was 
quickly washed with PBS to remove the blood from the ventricles and weighed. The heart 
was lysed with 1 ml of 0.5 M NaOH and neutralized with 6 M HCl. Radioactivity was 
determined in 20 μl of blood and a whole heart on an LS 6500 multipurpose scintillation 
counter (Beckman-Coulter). Palmitic acid uptake into the heart was normalized by the 
radioactivity of the blood and the heart weight.
Oil Red O staining—Neonatal CMs were cultured on coverslips and fixed in 4% 
paraformaldehyde. The left ventricle of the heart was frozen with O.C.T. compound and 
Cryomold Biopsy (Tissue-Tek). The heart tissue was cut into 10 μm thick sections on a glass 
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slide. Frozen sections were air-dried for 10 minutes at room temperature and fixed with 10% 
formalin for 5 minutes. After washing with PBS, the sections were dipped into 60% 
isopropyl alcohol three times and then put into Oil Red O working solution [0.5% Oil Red O 
(Sigma) dissolved in isopropyl alcohol (W/V)] for 15 minutes. The sections were washed 
with 60% isopropyl alcohol three times and then water for 30 minutes. Cover glasses were 
mounted with mounting medium. Images were obtained in a blinded manner and analyzed 
with ImageJ software (NIH).
Immunohistochemistry—The heart tissue was washed with PBS, fixed in 4% 
paraformaldehyde overnight, embedded in paraffin, and sectioned at 10-μm thickness onto a 
glass slide. After de-paraffinization, sections were stained with Picric acid sirius red (PASR) 
or Periodic acid-Schiff for evaluation of fibrosis or glycogen accumulation, respectively. 
Images were obtained in a blinded manner. The cross-sectional area of CMs was measured 
after wheat germ agglutinin (WGA) staining using ImageJ software (NIH).
Immunofluorescence staining—Rat neonatal CMs were cultured on coverslips, 
transduced with adenoviruses for 2 to 4 days, washed with PBS, and fixed in 4% 
paraformaldehyde for 10 minutes. Samples were permeabilized with PBST (0.5% Triton-X 
in PBS) for 15 minutes and blocked in 5% BSA, 5% goat serum in PBST for 30 minutes at 
37°C. Samples were incubated with specific antibodies at 4°C overnight, washed, and 
incubated with secondary antibody conjugated with Alexa Fluor 488, 555, or 594 dye (Life 
Technologies). Samples were washed with PBS and mounted on glass slides with mounting 
medium containing DAPI to stain nuclei (VECTASHIELD, Vector Laboratories). Cells were 
observed under a fluorescence microscope. Images were obtained in an unblinded manner.
Proximity Ligation Assay—The interaction between GSK-3α and PPARα was 
examined in situ using Duolink. Rat neonatal CMs were transduced with adenovirus 
harboring YFP-PPARα, followed by incubation with 100 μM or 500 μM of BSA-conjugated 
palmitic acid in the presence or absence of fenofibrate. After fixation, slides were incubated 
for 10 min at 95°C in antigen retrieval buffer (100 mM Tris, 5% urea, pH 9.5). Slides were 
then blocked for 4 hours at 4°C with PBS containing 5% normal goat serum. Anti-GSK-3α 
and anti-GFP-YFP primary antibodies were added (diluted 1:100 in blocking buffer) and 
slides were incubated in a humidity chamber overnight at 4°C. Slides were further blocked 
at 37°C in Duolink blocking buffer for 1 hour in a humidity chamber. Slides were then 
washed in Duolink Wash Buffer A twice at room temperature. PLA PLUS Anti-mouse and 
PLA MINUS Anti-rabbit probes were then incubated with slides in a preheated humidity 
chamber for 1 hour at 37°C. After washing in Wash Buffer A twice for 5 minutes, slides 
were incubated with Duolink Ligation Stock for 30 minutes at 37°C. After that, slides were 
washed in Wash Buffer A and incubated with Duolink Polymerase in Duolink Amplification 
Stock for 100 minutes at 37°C. After two washes with Wash Buffer B, slides were mounted 
with Duolink Mounting Medium with DAPI. Images were obtained in an unblinded manner.
• Quantification and Statistical Analysis
All values for continuous data are expressed as mean ± s.e.m. Statistical analyses were 
carried out by 2-tailed unpaired Student t test for 2 groups or 1-way ANOVA followed by 
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the Newman-Keuls post-hoc analysis for 3 groups or more, assuming independent variables, 
normal distribution, and equal variance of samples. Categorical variables were compared 
using Fisher’s exact test. A p value of less than 0.05 was considered significant. Statistical 
parameters can be found in the figure legends. Statistical analyses were performed using 
GraphPad Prism (GraphPad Software).
• Data and Software Availability
The RNA sequencing data on H9C2 cell lines transduced with PPARα mutants have been 
deposited in NCBI’s Gene Expression Omnibus and are accessible through GEO Series 
accession number GSE112309. The microarray data on the hearts of GSK-3α and GSK-3β 
knock-in mice have been deposited in NCBI’s Gene Expression Omnibus and are accessible 
through GEO Series accession number GSE112160.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
Fatty acids upregulate GSK-3α, which, in turn, phosphorylates PPARα at Ser280.
Ser280-phosphorylation stimulates biased gene expression favoring fatty acid uptake.
PPARα-Ser280 phosphorylation promotes the development of lipotoxic cardiomyopathy.
Fibrates inhibit Ser280-phosphorylation, thereby reversing cardiac lipotoxicity.
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Figure 1. Cardiac-specific GSK-3α haploinsufficiency ameliorates high-fat diet (HFD)-induced 
lipotoxic cardiomyopathy.
(A) Area-proportional Venn diagram representing the 26 genes significantly (p < 0.05) 
upregulated both in ob/ob (GSE16790) and db/db (GSE36875) mouse hearts, but not in 
streptozotocin-induced diabetic hearts (Type I DM) (GSE5606). (B) Pie chart illustrating the 
percent composition of Gene Ontology biological processes of the 26 common genes found 
in (A). Metabolic process (GO: 0008152) contains the largest gene set (13 genes), among 
which only GSK-3α is a kinase. (C) Immunoblots to evaluate nuclear GSK-3α activity in 
Nakamura et al. Page 30
Cell Metab. Author manuscript; available in PMC 2020 May 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
the hearts of wild-type (WT) mice fed a HFD or normal chow (NC) for the indicated 
periods. GSK-3α was immunoprecipitated from the nuclear fraction of heart lysates, 
followed by in vitro kinase assays with recombinant β-catenin. Recombinant GSK-3α 
protein was used as a positive control and immunoprecipitation with IgG was used as a 
negative control. (D) Quantification of the nuclear GSK-3α activity in (C) (n = 3). (E to L) 
GSK-3α cardiac-specific heterozygous knockout (GSK-3α cHKO) mice and heterozygous 
floxed (control) mice were fed a HFD or NC for 14 weeks. (E) Photograph of the hearts of 
control and GSK-3α cHKO mice fed a HFD or NC. (F) Left ventricular (LV) weight 
normalized by tibia length, a marker of cardiac hypertrophy (n = 8 (NC) and 22–24 (HFD)). 
(G and H) Diastolic function, as indicated by deceleration time (n = 8–15) (G), and the slope 
of the end-diastolic pressure-volume (PV) relation (EDPVR) (n = 5 (NC) and 9 (HFD)) (H). 
(I) Lipid accumulation in the hearts (Oil Red O staining, left). Scale bar, 100 μm. Inset scale 
bar, 20 μm. Quantification of myocardial lipid accumulation (right) (n = 6). (J) Palmitate 
oxidation in the hearts (n = 8–9 (NC) and 17 (HFD)). (K) Picric acid sirius red (PASR) 
staining, indicating cardiac fibrosis (left). Scale bar, 100 μm. Percentage of PASR positive 
areas (right) (n = 4). (L) mRNA expression related to cardiac metabolism, inflammation, and 
transcription factors in the hearts (n = 6). (M) Gene set enrichment analysis plot of Kyoto 
encyclopedia of genes and genomes (KEGG). PPAR signaling signatures in GSK-3α S21A 
knock-in (KI) and WT mice fed NC. NES denotes normalized enrichment score. FDR 
denotes false discovery rate. Error bars indicate s.e.m. * p<0.05, ** p<0.001. See also 
Figures S1 and S2 and Table S1.
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Figure 2. GSK-3α physically interacts with and phosphorylates PPARα at Ser280 in 
cardiomyocytes (CMs) and in the heart.
(A and B) Immunoprecipitation assays to test the interaction between endogenous GSK-3α 
and exogenously expressed PPARα. YFP-tagged PPARα or FLAG-tagged PPARα was 
overexpressed in CMs using adenovirus (A) or in transgenic mouse hearts under the control 
of the αMHC-promoter (B), respectively. (C) Co-immunoprecipitation assays testing the 
interaction between endogenous GSK-3α and endogenous PPARα in CMs. (D) In vitro 
binding assays testing the direct interaction between recombinant (r) GSK-3α and rPPARα. 
(E to G) Immunoprecipitation assays to identify the amino acids in PPARα responsible for 
the interaction with endogenous GSK-3α. (E) Schematic representation of rGST-fused 
PPARα fragments. (F) Schema of the immunoprecipitation assays. rGST-fused-PPARα-full 
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length (FL) or truncated PPARα (T1 to 5) was incubated with lysates extracted from 
cultured CMs, followed by pull-down with glutathione-sepharose and immunoblotting with 
anti-GSK-3α antibody. (G) Coomassie Brilliant Blue staining of rGST-PPARα-FL or 
truncated rGST-PPARα (T1 to T5) (left). Immunoblots testing the binding of endogenous 
GSK-3α to rGST-PPARα-FL or T1 to T5 (right). (H) Mass spectrometry analysis of the 
rGST-PPARα protein phosphorylated by GSK-3α in a kinase reaction. The MS/MS 
spectrum of the PPARα residue corresponding to Ser280 was increased at 80 Da, indicating 
phosphorylation. (I) Immunoblots showing Ser280 phosphorylation of endogenous PPARα 
in the hearts of WT mice fed a high-fat diet (HFD) or normal chow (NC) for 3 weeks. α-
sarcomeric actinin was used as a loading control. (J) Immunoblots showing pPPARα (S280) 
in the hearts of control or GSK-3α cHKO mice fed a HFD for the indicated period. See also 
Figure S3.
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Figure 3. Ser280 phosphorylation stimulates a subset of PPARα targets and promotes fatty acid 
uptake in cardiomyocytes.
(A) Immunoblots showing subcellular localization and expression of p-PPARα (Ser280) in 
cultured cardiomyocytes (CMs) treated with BSA-palmitic acid (PA) (0–500 μM) for 9 
hours. (B) Immunoblots examining the involvement of GSK-3α in the BSA-PA-induced 
increase in PPARα phosphorylation at Ser280 in CMs. CMs transduced with adenovirus 
harboring shRNA-GSK-3α or scramble were treated with the indicated concentrations of 
PA, followed by nuclear extraction and immunoblotting. (C) Immunoblots showing the 
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expression of p-PPARα (Ser280) in the nucleus of CMs treated with BSA-fatty acid cocktail 
for 9 hours. (D) Clustergram heat map of RNA-sequencing data. H9C2 cells were 
transduced with PPARα-wild type (WT), -S280A (SA) or -S280D (SD) mutant, or YFP 
alone as a control. Gene sets having 1) a fold difference of 1.5 or more between SA and SD 
and 2) a WT expression level located between SD and SA are shown in the heat map. (E) 
Gene set enrichment analysis plots of PPARα-SD (vs WT) showing upregulated signatures 
related to energy metabolism. Gene expression was determined by RNA-seq data. (F) qRT-
PCR validation of expression of genes related to lipid metabolism and oxidative 
phosphorylation in CMs transduced with adenovirus harboring a YFP-PPARα-S280A or -
S280D mutant or YFP alone as a control (n = 8–10). (G) Fatty acid uptake into CMs 
transduced with the indicated adenovirus. 3H-palmitate (left) and combined 3H-palmitate 
and 3H-oleate (right) incorporation into CMs was measured by scintillation counting (n = 4–
5). (H) Relative oxygen consumption rate (OCR) of CMs transduced with the indicated 
adenovirus was measured in a 24-well Seahorse experiment in the presence of 500 μM of 
BSA-PA. Mitochondrial fatty acid oxidation (FAO) was evaluated by etomoxir-inhibitable 
OCR. Histograms show FAO rate (the ratio of FAO versus total OCR) (n = 5). (I) FAO rate 
in CMs transduced with the indicated adenovirus, measured in a 96-well Seahorse 
experiment in the presence of 500 μM of BSA-fatty acid cocktail (n = 8). (J and K) Oil Red 
O staining of CMs transduced with the indicated adenovirus in the presence or absence of 
BSA-PA (500 μM) (n = 5) (J) or in the presence of BSA-fatty acid cocktail (500 μM) (n = 6) 
(K). BSA alone was used as a control (PA 0 μM). Scale bars, 100 μm (upper panel) and 20 
μm (lower panel). Error bars indicate s.e.m. * p < 0.05, ** p < 0.001. See also Figure S4 and 
Table S2.
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Figure 4. PPARα-Ser280 phosphorylation enhances both interaction with RXRα and PPRE 
binding.
(A) Representative immunoblots showing the interaction between YFP-PPARα-wild type 
(WT), -S280D (SD) or -S280A (SA) mutant and RXRα in cardiomyocytes (CMs) in vitro. 
YFP alone was used as a control. (B) PPRE-luciferase reporter assay using a series of 
alanine mutations to evaluate the effect of the indicated basic residues on the activity of 
PPARα-S280D (n = 12). ## p<0.001 compared to PPARα-S280D. (C) Chromatin 
immunoprecipitation (ChIP) assays using CMs transduced with adenovirus (Ad)-YFP-
PPARα-WT, -SD, -SA, or YFP alone as a control. DNA was amplified by PCR with specific 
primers flanking the promoter of the indicated genes containing the PPARα-binding motif. 
PCR using input DNA as template served as an internal control. The data shown are 
representative of three independent experiments. (D) ChIP assays using specific primers 
flanking the promoter of the indicated genes containing the PPARα-binding motif. The data 
shown are representative of three independent experiments. (E) Double-stranded oligo pull-
down assays, using biotinylated oligos containing the specific PPRE sequences in the 
indicated gene promoters. Recombinant GST-PPARα-WT or -SA was subjected to in vitro 
kinase assays using recombinant GSK-3α prior to the oligo pull-down assays. An oligo 
containing a PPRE with mutations in four base pairs was used as a negative control. (F) 
Venn diagram showing the number of genes in the rat genome containing the specific 
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PPRE/DR1 motif (shown in Figure S5F) in their promoters. The numbers of overlapping 
genes in the Venn diagram (red circle) were significantly different (p=0.0002, Fisher’s exact 
test). See also Figure S5.
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Figure 5. Phosphorylation of PPARα at Ser280 is critical for the development of lipotoxic 
cardiomyopathy.
(A) Heatmap of metabolites associated with fatty acids/glycerol, glycolysis and BCAA 
metabolism in the hearts of wild-type (WT) and heterozygous PPARα-S280A knock-in (KI) 
mice at baseline, measured by metabolomics. (B) Histograms showing myocardial free fatty 
acids in the hearts of WT and heterozygous PPARα-S280A KI mice (n = 5). (C to E) WT 
and heterozygous PPARα-S280A KI mice were fed a high-fat diet (HFD) or normal chow 
(NC) for 8 weeks. (C) Left ventricular (LV) weight normalized by tibia length (n = 5). (D) 
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The slope of the end-diastolic pressure-volume (PV) relation (EDPVR), a marker of 
diastolic function (n = 5–8). (E) Oil Red O staining of the heart sections (left). Scale bar, 50 
μm. Quantification of myocardial lipid accumulation (right) (n = 6). (F to M) Either 
PPARα-WT or PPARα-S280D (SD) mutant was expressed in the hearts of WT mice 
(C57BL/6J background) fed NC for 8 weeks via adeno-associated virus (AAV)-mediated 
gene delivery. AAV-empty injection (Emp or Empty) was performed as a control. (F) 
Representative immunoblots showing the expressions of p-PPARα (Ser280), PPARα-
S280D and total PPARα in the heart and skeletal muscle. Histogram indicates the expression 
levels relative to Histone H3 (n = 8). (G) LV weight normalized by tibia length (n = 5–7). 
(H) LV posterior wall thickness on diastole (LVPWd), a marker of hypertrophy (n = 5–6). (I) 
Deceleration time, a marker of diastolic function (n = 5–6). (J) The slopes of EDPVR (left) 
and Tau (right), both markers of diastolic function (n = 4–6). (K) Fatty acid oxidation (FAO) 
rate in CMs isolated from the hearts of mice transduced with the indicated AAV (n = 5). (L) 
Oil Red O staining of the heart sections (left). Scale bars, 50 μm. Quantification of 
myocardial lipid accumulation (right) (n = 4–6). (M) Picric acid sirius red (PASR) staining 
indicating cardiac fibrosis in the heart sections (left) and the percentage of PASR positive 
areas (right). Scale bars, 200 μm (n = 4–7). Error bars indicate s.e.m. * p<0.05, ** p<0.001. 
See also Figure S6 and Table S3.
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Figure 6. Fenofibrate, a PPARα ligand, inhibits GSK-3α-mediated PPARα-Ser280 
phosphorylation, thereby ameliorating lipotoxic cardiomyopathy.
(A) Immunoblots examining the effect of fenofibrate, a PPARα agonist, on PPARα-Ser280 
phosphorylation in cardiomyocytes (CMs) in the presence or absence of 500 μM of BSA-
palmitic acid (PA). (B to E) Wild-type (WT) mice were fed a high-fat diet (HFD) in the 
presence or absence of fenofibrate (Feno) for the indicated periods, as shown in Figure S7C. 
(B) Immunoblots examining the effect of fenofibrate on PPARα-Ser280 phosphorylation in 
the hearts. (C) Left ventricular (LV) weight normalized by tibia length (n = 8–12). (D) The 
slope of the end-diastolic pressure-volume (PV) relation (EDPVR), a marker of diastolic 
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function (n = 5–11). (E) Oil Red O staining of heart sections after 14 weeks of HFD in the 
presence or absence of fenofibrate (left). Scale bar, 100 μm. Quantification of myocardial 
lipid accumulation (right) (n = 5). (F) The differential effect of fenofibrate on PPRE-
luciferase reporter activity in H9C2 cells transduced with PPARα-WT or PPARα-S280D 
mutant in the presence of a high concentration of fatty acid (500 μM of PA) or BSA control. 
YFP alone was used for background extraction (n = 6). (G) Fatty acid oxidation (FAO) rate 
in CMs in the presence of 50 μM or 500 μM of PA. Total oxygen consumption rate (OCR) in 
CMs transduced with the indicated adenoviruses was measured by 96-well Seahorse 
experiment and mitochondrial FAO was evaluated by etomoxir-inhibitable OCR (n = 18–23 
(WT) and 6–7 (S280D)). (H) Oil Red O staining of rat neonatal CMs transduced with the 
indicated adenovirus in the presence or absence of fenofibrate with 50 μM or 500 μM of 
BSA-PA (left). Scale bar, 50 μm. Quantification of myocardial lipid accumulation (right) (n 
= 6). (I and J) Immunoprecipitation assays showing the interaction between endogenous 
GSK-3α and YFP-PPARα or YFP alone as a control in CMs treated with 100 μM or 500 
μM of BSA-PA in the presence or absence of 10 μM of fenofibrate (I) and quantification of 
the data (n = 4) (J). (K) Proximity Ligation Assay (PLA) showing the in situ interaction 
between endogenous GSK-3α and YFP-PPARα in CMs treated with 100 μM or 500 μM of 
PA in the presence or absence of 10 μM of fenofibrate. PLA was performed using anti-
GSK-3α and anti-GFP-YFP antibodies. Red color indicates localization in close proximity. 
Scale bar, 10 μm. (L) Immunoblots examining GSK-3α activity in failing human hearts in 
the presence (n = 7) or absence (n = 14) of diabetes. See also Figure S7 and Table S4.
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Table 1.
Top 10 upregulated KEGG gene sets in GSK-3α KI (vs WT) mouse heart.
GS follow link to MSigDB SIZE ES NES NOM p-val FDR q-val
1 KEGG_COMPLEMENT_AND_COAGULATION_CASCADES 45 0.76 2.52 0 0
2 KEGG_PPAR_SIGNALING_PATHWAY 60 0.66 2.31 0 0.001
3 KEGG_GLYCINE_SERINE_AND THREONINE_METABOLISM 28 0.74 2.22 0.001 0.001
4 KEGG_CYSTEINE_AND_METHIONINE_METABOLISM 29 0.72 2.15 0 0.002
5 KEGG_SPLICEOSOME 90 0.48 1.77 0 0.131
6 KEGG_PHENYLALANINE_METABOLISM 16 0.65 1.75 0.019 0.135
7 KEGG_TRYPTOPHAN METABOLISM 33 0.56 1.74 0.006 0.131
8 KEGG_BASAL_TRANSCRIPTION_FACTORS 30 0.57 1.72 0.012 0.131
9 KEGG_PROTEASOME 42 0.53 1.72 0.011 0.123
10 KEGG_AMINO_SUGAR_AND_NUCLEOTIDE_SUGAR_METABOLISM 42 0.54 1.71 0.001 0.115
The PPAR signaling pathway is most significantly enriched among energy metabolism-related gene sets in the hearts of GSK-3α knock-in (KI) 
mice compared to wild-type (WT) mice at three months of age, a time point before the development of cardiomyopathy in GSK-3α KI mice.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Anti-rabbit monoclonal 
phospho-GSK-3α (Ser21) 
(36E9)
Cell Signaling 9316
Anti-rabbit monoclonal 
GSK-3α (D80E6)
Cell Signaling 4337
Anti-rabbit monoclonal 
GSK-3α (D80D1) XP
Cell Signaling 4818
Anti-rabbit monoclonal 
GSK-3α/β (D75D3) XP
Cell Signaling 5676
Anti-rabbit polyclonal 
phospho-GSK-3α/β (Ser21/9)
Cell Signaling 9331
Anti-rabbit monoclonal 
GSK-3β (27C10)
Cell Signaling 9315
Anti-mouse monoclonal 
GSK-3α (H-12)
Santa Cruz sc-5264
Anti-rabbit polyclonal GSK-3β 
(H-76)
Santa Cruz sc-9166
Anti-rabbit polyclonal PPARα Cayman Chemical 101710
Anti-rabbit polyclonal PPARα Abcam ab24509
Anti-rabbit polyclonal RXRα 
(D-20)
Santa Cruz sc-553
Anti-rabbit polyclonal 
RXRα/β/γ (ΔN197)
Santa Cruz sc-774X
Anti-rabbit monoclonal β-
Catenin (6B3)
Cell Signaling 9582
Anti-rabbit polyclonal 
phospho-β-catenin (Ser33/37/
T41)
Cell Signaling 9561
Anti-rabbit polyclonal Akt Cell Signaling 9272
Anti-rabbit polyclonal 
phospho-Akt (Ser473)
Cell Signaling 9271
Anti-rabbit polyclonal Histone 
H3
Cell Signaling 9715
Anti-rabbit monoclonal 
GAPDH (14C10)
Cell Signaling 2118
Anti-rabbit monoclonal GFP 
(D5.1) XP
Cell Signaling 2956
Anti-rabbit polyclonal GST Cell Signaling 2622
Anti-mouse monoclonal α-
actinin (Sarcomeric)
Sigma-Aldrich A7811
Anti-mouse IgG, HRP-linked 
antibody
Cell Signaling 7076
Anti-rabbit IgG, HRP-linked 
antibody
Cell Signaling 7074
Anti-rabbit polyclonal 
Troponin T antibody
Abcam 45932
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REAGENT or RESOURCE SOURCE IDENTIFIER
Goat anti-mouse IgG secondary 
antibody, Alexa Fluor 488
Thermo Fisher Scientific A-11029
Goat anti-rabbit IgG secondary 
antibody, Alexa Fluor 488
Thermo Fisher Scientific A-11034
Goat anti-rabbit IgG secondary 
antibody, Alexa Fluor 594
Thermo Fisher Scientific A-11037
Clean-Blot IP Detection 
Reagent (HRP)
Thermo Fisher Scientific 21230
Anti-rabbit polyclonal 
phospho-specific PPARα 
(Ser280)
GeneScript This paper
Bacterial and Virus Strains
Subcloning Efficiency DH5α 
Competent Cells
Thermo Fisher Scientific 18265017
One Shot BL21(DE3) 
Chemically Competent E. coli
Thermo Fisher Scientific C600003
BAC clone BACPAC RP24–545F24
Biological Samples
Human heart samples Taipei Veterans General 
Hospital
This paper
Chemicals, Peptides, and Recombinant Proteins
Anti-GFP mAb-Magnetic beads MBL D153–11
Anti-FLAG M2 Affinity Gel Sigma-Aldrich A2220
Protein A/G PLUS-Agarose Santa Cruz sc-2003
Glutathione Sepharose 4B VWR/GE 17–0756-01
GSK3α protein, active Millipore 14–492
GSK3β protein, active Millipore 14–306
Recombinant GST-PPARa 
(full-length and truncated)
This paper N/A
Recombinant GST-β-catenin This paper N/A
PPARα LBD (human 
recombinant)
Cayman Chemical 10009088
Recombinant GSK-3α This paper N/A
IPTG Invitrogen 15529–019
FuGENE 6 Reagent VWR/Promega E2691
LipofectamineTM 2000 
Transfection Reagent
Invitrogen 11668–019
Palmitic acid Sigma-Aldrich P0500
Oleic acid Sigma-Aldrich O1008
Linoleic acid Sigma-Aldrich L1376
Bovine Serum Albumin Boston BioProducts P753
Palmitic Acid, [9,10–3H(N)]-, 
5mCi (185MBq)
Perkin Elmer NET043005MC
Oleic Acid, [9,10–3H(N)]-, 
1mCi
Perkin Elmer NET289001MC
Etomoxir sodium salt hydrate Sigma-Aldrich E1905
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REAGENT or RESOURCE SOURCE IDENTIFIER
2-Deoxy-D-glucose Sigma-Aldrich D8375
L-Carnitine hydrochloride Sigma-Aldrich C0283
Sodium Pyruvate Sigma-Aldrich P4562
Fenofibrate Sigma-Aldrich F6020
WY-14643 R&D Systems, Tocris 1312
Rodent Diet with 60% kcal% 
fat
Research Diets D12492
Rodent Diet with 10% kcal% 
fat
Research Diets D12450B
High-fat diet containing 0.2% 
(wt/wt) fenofibrate
Research Diets This paper
High-fat diet without 
Fenofibrate
Research Diets This paper
Insulin solution human Sigma-Aldrich I9278
2,2,2-Tribromoethanol Sigma-Aldrich T48402
Oil Red O solution in 0.5% in 
isopropanol
Sigma-Aldrich O1391
Phosphatase Inhibitor Cocktail 
3
Sigma-Aldrich P0044
Protease Inhibitor Cocktail Sigma-Aldrich P8340
Maxima SYBR Green/ROX 
qPCR Master Mix (2x)
Thermo/Fermentas K0223
TRIzol Reagent (Ambion) Life Technologies 15596–018
Adenosine 5’-diphosphate 
sodium salt
Sigma-Aldrich A2754
Collagenase Type 2 CLS2 Worthington LS004177
Percoll GE Healthcare 17–0891-01
Biotinylated Thrombin EMD Millipore 69672–3
Streptavidin Agarose EMD Millipore 69203–3
Critical Commercial Assays
XF24 Extracellular Flux 
Analyzer
Seahorse Bioscience https://www.agilent.com/en/products/cell-analysis-(seahorse)/seahorse-analyzers
XF96 Extracellular Flux 
Analyzer
Seahorse Bioscience https://www.agilent.com/en/products/cell-analysis-(seahorse)/seahorse-analyzers
BriteLite Plus Perkin Elmer 6066761
Luciferase assay system VWR/Promega E1501
Duolink In Situ PLA probe 
anti-Mouse MINUS
Sigma-Aldrich 92004–0030
Duolink In Situ PLA probe 
anti-Rabbit PLUS
Sigma-Aldrich 92002–0030
TnT T7 Coupled Reticulocyte 
Lysate System
VWR/Promega L4610
QIAGEN HiSpeed Plasmid 
Maxi Kit
QIAGEN 12663
QIAGEN HiSpeed Plasmid 
Midi Kit
QIAGEN 12643
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REAGENT or RESOURCE SOURCE IDENTIFIER
QIAprep Spin Miniprep Kit QIAGEN 27104
QIAquick PCR Purification Kit QIAGEN 28106
QIAquick Gel Extraction Kit QIAGEN 28706
Deposited Data
GSK-3α/β knock-in mice 
microarray data
Matsuda, T. et al., 2008 GSE112160
PPARα mutants RNaseq data This paper GSE112309
Experimental Models: Cell Lines
H9C2 Oka, S. et al., 2011 N/A
HEK293 Maejima, Y. et al., 2013 N/A
Experimental Models: Organisms/Strains
Mouse: GSK-3α heterozygous 
floxed
Gift from Dr. P.S. Klein 
(University of 
Pennsylvania)
N/A
Mouse: GSK-3β floxed Gift from Dr. C.J. Phiel 
(Nationwide Children’s 
Hospital)
He, F. et al., 2010.
Mouse: GSK-3α-Ser21Ala knock-inGift from Dr. D.R. 
Alessi (University of 
Dundee)
N/A
Mouse: GSK-3β-Ser9Ala knock-in Gift from Dr. D.R. 
Alessi (University of 
Dundee)
N/A
Mouse: α-myosin heavy chain 
promoter-driven heterozygous 
Cre transgenic
Gift from Dr. M.D. 
Schneider (Imperial 
College London)
N/A
Mouse: α-myosin heavy chain 
promoter-driven FLAG-PPARα 
transgenic
Gift from Dr. D. Kelly 
(University of 
Pennsylvania)
N/A
Mouse: C57BL/6J Jackson Laboratory JAX 000664
Mouse: ob/ob: B6.Cg-Lepob/J Jackson Laboratory JAX 000632
Mouse: PPARα-Ser280Ala knock-inThis paper N/A
Rat: Primary cultured neonatal 
ventricular cardiomyocytes
Harlan 1-day-Crl:(WI)BR-Wistar rats
Oligonucleotides
Oligonucleotides used in this 
study are provided in Table S5
This paper NCBI PRIMER-BLAST
Recombinant DNA
pDC316 shuttle vector Microbix N/A
pDC316-YFP shuttle vector Sadoshima lab Maejima, Y. et al., 2013
pDC316-FLAG shuttle vector Sadoshima lab Maejima, Y. et al., 2013
pDCSilencer Microbix N/A
pBHGloxΔE1.3 Cre Microbix N/A
pCold-GST Takara/Clontech 3372
CTNNB1 (untagged)-Human 
catenin, beta 1
Origene SC107921
GSK3 alpha pMT2 Addgene 15896
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REAGENT or RESOURCE SOURCE IDENTIFIER
pPPRE-tk-luciferase reporter Gift from Dr. Ronald 
Evans (Salk Institute)
N/A
pCITE-GSK-3α This paper N/A
pL451 Gift from Dr. Takeda 
(Osaka University)
N/A
pMCS-DTA Gift from Dr. Takeda 
(Osaka University)
N/A
pMCS-Neo-PPARα-S280A-DTA This paper N/A
pCold-GST-PPARα-full length This paper N/A
pCold-GST-PPARα-truncate 1 This paper N/A
pCold-GST-PPARα-truncate 2 This paper N/A
pCold-GST-PPARα-truncate 3 This paper N/A
pCold-GST-PPARα-truncate 4 This paper N/A
pCold-GST-PPARα-truncate 5 This paper N/A
pDC316-YFP-PPARα-wild type This paper N/A
pDC316-YFP-PPARα-S280A This paper N/A
pDC316-YFP-PPARα-S280D This paper N/A
pDC316-YFP-PPARα-S280E This paper N/A
pDC316-YFP-PPARα-WT-H440A This paper N/A
pDC316-YFP-PPARα-WT-H440Q This paper N/A
pDC316-YFP-PPARα-WT-K448A This paper N/A
pDC316-YFP-PPARα-WT-K448N This paper N/A
pDC316-YFP-PPARα-WT-K449A This paper N/A
pDC316-YFP-PPARα-WT-K449N This paper N/A
pDC316-YFP-PPARα-WT-K448A/K449AThis paper N/A
pDC316-YFP-PPARα-WT-K448N/K449NThis paper N/A
pDC316-YFP-PPARα-WT-H440A/K448A/K449AThis paper N/A
pDC316-YFP-PPARα-WT-H440Q/K448N/K449NThis paper N/A
pDC316-YFP-PPARα-WT-H440A This paper N/A
pDC316-YFP-PPARα-S280D-H440QThis paper N/A
pDC316-YFP-PPARα-S280D-K448AThis paper N/A
pDC316-YFP-PPARα-S280D-K448NThis paper N/A
pDC316-YFP-PPARα-S280D-K449AThis paper N/A
pDC316-YFP-PPARα-S280D-K449NThis paper N/A
pDC316-YFP-PPARα-S280D-K448A/K449AThis paper N/A
pDC316-YFP-PPARα-S280D-K448N/K449NThis paper N/A
pDC316-YFP-PPARα-S280D-H440A/K448A/K449AThis paper N/A
pDC316-YFP-PPARα-S280D-H440Q/K448N/K449NThis paper N/A
pDC316-GSK-3α This paper N/A
shRNA-GSK-3α #1 This paper N/A
shRNA-GSK-3α #2 This paper N/A
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REAGENT or RESOURCE SOURCE IDENTIFIER
shRNA-GSK-3α #3 This paper N/A
pBluescript II Maejima, Y. et al., 2013 N/A
AAV-DJ/8-CMV UPenn Vector Core N/A
AAV-DJ/8-CMV-PPARα-wild type This paper N/A
AAV-DJ/8-CMV-PPARα-S280D This paper N/A
Software and Algorithms
R version 3.3.1 The R Project https://www.r-project.org/
CLC Genomics Workbench 8.5 
version
Qiagen http://www.clcbio.com/products/clc-genomics-workbench/
GSEA ver 2.0 Broad institute of MIT 
and Harvard
http://software.broadinstitute.org/gsea/
IPA pathway analysis software Qiagen https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/
MEME Suite ver 5.0.2 The MEME SUITE http://meme-suite.org/
UCSC Genome Browser UCSC http://genome.ucsc.edu/
ImageJ NIH https://imagej.nih.gov/ij/
Prism version 6 GraphPad https://www.graphpad.com
Metaboanalyst ver 3.0 MetaboAnalyst http://www.metaboanalyst.ca/
MultiExperiment Viewer ver4.9.0 MeV http://mev.tm4.org/#/welcome
Other
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